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 When I left Kentucky to start graduate school, I was excited to start something 
new but mostly considered it a necessary evil and a means to the ends that I wished to 
pursue later in life.  I knew that, in the process of getting a top-notch education, I would 
probably enjoy my mid-20’s and make the transition from a “college-kid” to an “adult” in 
a fun city, Atlanta.  At the time, the overwhelming feeling was that I needed to get this 
over with as quickly and painlessly as possible and get on to the real world.  However, as 
time passed, this feeling began to fade and Atlanta became my comfort zone.   By the 
time that the end of the journey was in sight, what I thought was going to be a “thank 
goodness and good riddance” moment has turned out to be a feeling of mixed emotions 
and of strong attachment to the people and the place that have filled my life for the past 5 
1/2 years.  Whether the transition to adulthood that I mentioned above ever actually 
happened is tremendously debatable.  Regardless, the one thing I did learn was that 
working toward a Ph.D., like any experience in life, is something to savor and not a 
constant race to the end.  In this section of my thesis, I will attempt to acknowledge those 
who have enhanced my grad school experience and have helped to make Atlanta a great 
place to live. 
 First and foremost, I owe a tremendous amount of gratitude to my thesis 
coadvisors, W. Robert Taylor and Robert E. Guldberg (aka “Bob T & G” or “the Bobs”).  
It has always been difficult to explain why I have been coadvised by a mechanical 
engineer at Georgia Tech and a cardiologist at Emory.  I have also often said that it is 
pretty to easy to see why being coadvised as a graduate student doesn’t typically work 
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out, especially when the professors’ primary interests do not have significant overlap.  
However, the Bobs provided the perfect mix of intellectual support, selflessness, freedom 
to find my own way and satisfy my own curiosities, and an environment that has allowed 
me to grow as an independent thinker.  As advisors, they have always remained 
supportive, yet demanded that I get the best from myself, and for that, I am appreciative.  
Moreover, they have tried to ensure that I have every opportunity to move on and gain 
my own successes, independent of their own.  Additionally, both Bobs have always 
served as friends and been truly compassionate about my well-being and life outside of 
research, which has been equally integral to my motivation and peace of mind during 
grad school.  Overall, this unique setup between the Bobs has allowed me to gain an 
incredibly meaningful, diverse, and rich experience.   
I also am thankful for the advisement of my thesis committee members.  Dr. 
Skrinjar has been a tremendous resource for imaging and image processing related work.  
Dr. Bellamkonda has remained an inquisitive member of the group that has provided 
expertise in vascular contrasts, ensured that I understood the big picture of my work, and 
been a valuable mentor in my pursuits and interests for postdoctoral work.  Dr. Harrison 
has provided a valuable clinical perspective in addition to many valuable insights into my 
understanding of vascular biology.  Dr. McIntire has supplied additional expertise on 
vascular biology from a cellular perspective and has been integral to progression of this 
project.  
I am also grateful to the staff and administrators within the Emory Division of 
Cardiology, IBB, and BME, which have made my life much easier during grad school.  
In particular, I would like to thank Dr. Nerem for granting me the opportunity to work in 
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his lab when I first came to Georgia Tech.  On a larger scale, he has created a cutting 
edge scientific community within IBB that is equipped with all of the necessary pieces to 
ensure development and success of the researchers there.  On a personal level, he has 
always taken the time to provide meaningful advice and valuable contacts within the 
scientific community.  In addition, I am grateful to Don Giddens, Larry McIntire, Ajit 
Yoganathan, and Steve DeWeerth for their impeccable leadership and dedication to 
building and evolving a BME department that is second to none.  Lastly, I would like to 
thank Tracey Couse for sharing her remarkable histology knowledge and skills during her 
tenure at IBB.      
I am also sincerely indebted to my colleagues within IBB wing 2D, the Emory 
Division of Cardiology, and other students of BME program.  Many of these coworkers 
and fellow students have also served double duty as my closest friends.  Wing 2D was 
my first real grad school residence as I began work on the micro-CT imaging studies.  I 
must acknowledge that the combined Guldberg, Garcia, Levenston, and Boyan labgroups 
share a great deal of camaraderie and also possess incredible scientific capacity, which 
combine to form an extremely positive academic work environment.  I especially want to 
think Andres Garcia and his lab, which was actually my first home in wing 2D during my 
first research rotation.  Andres has remained a close friend and provided advice and 
opinions in his typical unabashed style on topics from research, to potential postdocs, to 
the current state of my alma mater’s sports teams.  I also want to say thanks to my close 
affiliates in the Levenston labs, particularly Chris Wilson, Ashley Palmer, and Eric 
Vanderploeg, with whom it has been intellectually resourceful and a joy to work over the 
years, not to mention the many good times that we have shared outside the lab.  
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From the Guldberg lab, I first want to thank Blaise Porter for “grandfathering” me 
into a fun working environment, even though he once almost killed me mountain biking 
in Vail.  Thanks for taking the focus off of my own exploits through your propensity for 
mashed potato thievery and other such adventures.  I also have to throw a shout out to the 
original master of ceremonies, Galen Robertston (aka G-Rob), whose hosting of the grind 
on Bourbon Street is a memory that will never fade.  I next want to thank Chris Gemmiti 
for being my partner in crime in many Guldberg trips/festivities and also for his ABC 
connections, golf outings, and untouchable super bowl extravaganzas.  I want to thank 
Dr. Alex Peister, an excellent newer member of the lab, for her cheerful demeanor and 
offering to help proofread this thesis.  I also know that the lab is in good shape with the 
remaining new and experienced students of the lab: Rhima Coleman, Megan Oest, Yash 
Kolambkar, Ken Dupont, Mela Johnson, Joel Boerckel, Chris Dosier, and Eric Deutsch.      
Next, I must mention Srin Nagaraja and Angela Lin, fellow members of the Guldberg 
lab, along with Catherine Reyes, whom comprise my co-conspirators in the official 
activities of “the corner”.  Srin, we’ve had some great times, especially on conference 
trips and thrashing the competition in IM basketball over the years.  Angela, you’ve been 
a great asset to me in the lab in terms helping with micro-CT, mechanical testing, and 
critiques of my writing.  However, your contributions far exceed lab-related help, and 
we’ve shared many memories, none of which can be overshadowed by your trip up to 
Kentucky for Derby’06.  Cathy, you’re an amazingly gifted person with a fantastic 
outlook and persona, and your husband is ok too.  Speaking of Dr. Gersbach, Charlie, we 
became good friends from the start of grad school, and if it weren’t for a little coaching 
from you, I probably would’ve drowned during my first triathlon.    
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From the Taylor lab, there are also many people to whom I owe many thanks.  
First off, thanks to Fadi Alameddine for being my first mentor in using animal models 
and in angiogenesis research.  Exposure to you and all of the many cardiology fellows 
that have passed through the lab has provided a diversity of perspectives during grad 
school.  Just as the other fellows that have come before you, the most recent duo, Parker 
Grow and Juan Velasquez, have been a joy to work with and provided great intellect and 
positive contributions to the dynamic within the lab.  I also am grateful for assistance on 
this project from the instructors, postdocs, and other members of the lab including Patrick 
Cowan, Diane Sutcliffe, Giji Joseph, Daiana Weiss, Elethia Woolfolk, and Natalia 
Landazuri.  I owe a special thanks Patrick for teaching me about the “soft touch”, Diane 
for taking care of my last minute ordering needs, Giji for assistance with histology, and 
Daiana for an immeasurable amount of help in maintenance of the animal colonies and in 
other technical aspects of the project. 
Lastly, I owe a special thanks to my fellow Taylor lab grad students.  Between the 
shared lunches and many hours in the lab, we have, to say the least, kept each other on 
our toes with our constant ribbing of one another.  To Matt Whalin, the human 
encyclopedia, I owe many thanks for sharing his significant knowledge and contributing 
to the molecular and cell biology related aspects of this project.  As Matt and I finish up 
in the lab, I am assured that the grad student contingent remains a formidable group that 
includes the following cast of characters: Katie Maiellaro, Scott “Scrob” Robinson, 
“Young Nicolas” Nick Willett, and Ebony Washington.  Katie, as Scott and Patrick have 
always said, you’re pretty cool for a dude with long hair.  In all seriousness, you’re one of 
the most sincere, upbeat, and fun people I’ve been around, and you have always cheered 
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me up whenever I’ve had a bad day.  Nick, your laid back, Colorado cool has been a 
great fit to our group, so it’s on your shoulders to keep the good karma going long term.                          
I owe many good times during grad school to Torrence Welch, Neal Weinrich, 
and Scott Robinson, residents of the Heights at Cheshire Bridge (and the revelers of the 
many fine establishments in this area).  Scrob, between co-hosting “celebrations of life”, 
Harvey’s heroics at Okemo, late night lessons in gang symbols, tailgating with big shot 
CEO’s, mountain biking, triathlons, dominating all takers under the alias of team tanktop, 
attending Poison and many other concerts, and futile attempts at dismissing the common 
appraisal of us as the division of cardiology meatheads, the good times have kept rolling.  
Chunk/Maple I am sorry that many of the aforementioned activities have likely 
contributed to your negligent care, but just think of it as fate catching up to you for the 
annoying car rides.   
To King Big Head’s household, I would like to express much gratitude for 
making halloween one of my favorite holidays.  Special recognition goes to John Wilson 
for crafting a giant paper mache head with Matt’s face on it, which could’ve been the 
most entertaining costume in history.  I must also mention that the frequent cookouts and 
weekend mountain biking trips enjoyed with you guys kept me sane after long 
workweeks.  I owe tremendous gratitude to Matt (Big Head) Rhyner for planning and 
faithfully participating in all of these events.  Alongside this group, I must also say thanks 
to Sean (PSJI) Sullivan, with whom I forged a bond the first time I met on grad student 
recruiting weekend when I realized (after Sean talked for 45 consecutive minutes without 
taking a breath) that I had finally found someone that might be able to supplant my own 
knowledge of college basketball.  You and Matt were the go to guys when looking for 
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company on the many road trips to Nashville and the Kentucky Derby, with the “collars 
up” derby being an experience for the ages.   The entertainment value of the many 
consecutive ABC, Golden Buddha, NBA, PT Fridays goes without saying.  
I must also thank my roommates from grad school, starting with the 
Pennsylvanians, Jeff Gross and Blaine Zern.  Jeff, we’ve shared some great times since 
we became friends on day one of grad school.  You’re a stand-up guy with an incredibly 
bright future.  I still say you owe me for your marriage to Taryn for dragging you to the 
mixer that night at Twain’s.  BZ, exploits as the channel 4 news team, hand prints on the 
hallway walls, feats of strength from the balcony, and many IM sports highlight the 
memories from our year in apartment 1513.  I must finally thank Bryan Marshall for 
sharing his home and giving me a place to stay for the last few months of grad school.  
Although you’re a Hoosier, I admire, not only your quirky dance moves, but also your 
intellect, kindness, and energy. 
Next, I must thank those closest to me.  First, I would like to thank my better half, 
Gina Addington.  You have been a constant source of love and support, and I’m sure that 
the sustenance you provided was the only reason that I was able to endure the emotional 
and intellectual challenges that I had to overcome during the last few months of grad 
school.  I also appreciate your patience, openness, and support as I try to figure what’s 
going to be next in life.  You and your parents have provided a much-needed outlet from 
school and become a home away from home for me.   
Finally, I must thank my family.  First, I want to thanks my grandparents, Henry 
and Wada Winn, for the exemplary lives they’ve led, their constant love and support, and 
always greeting me with a hug that made me glad to be home.  I want to thank Jennifer 
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and Brad Shelby for making a great sister / brother-in-law combo that I infinitely enjoy 
spending time with during our visits to see each other.  I especially want to commend 
Brad for his love and unwavering support of my sister, and I want to thank Jenni for 
being a role model, setting the bar high, and paving a path that has made my own pursuits 
clearer and easier to obtain.  I’m very proud to call you “sis”.  Lastly, I want to thank my 
parents.  It’s impossible to describe the respect and admiration that I have for you and the 
lives that you’ve built for yourselves.  I want to say thanks for your constant love and 
support and helping me to obtain all of my dreams.  You’ve given me the utmost freedom 
to make my own decisions in life, and your impeccable work ethic and exemplary model 
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 Postnatal vascular growth is a complex process involving multiple cells types 
whose functionality is orchestrated by a variety of soluble extracellular growth factors, 
mechanical stimuli, and matrix derived cues.  The central goal for this dissertation project 
was to elucidate the role of osteopontin, a non-collagenous extracellular matrix protein, in 
postnatal vascular growth.    
 At the onset, we concluded that the current methods for measurement of 
vascularity in small animal models were lacking.  To address this shortcoming, we 
pursued micro-CT imaging for analysis of three-dimensional blood vessel architecture.  
We were able to demonstrate that micro-CT imaging provides an objective, quantitative, 
and three-dimensional methodology for evaluation of vascular networks that has broad 
applicability to preclinical studies. 
Next, we sought to apply the developed imaging techniques along with other 
complementary methodologies to explore the role of osteopontin in postnatal vascular 
growth.  Osteopontin was previously known to elicit survival, migration, and other 
relevant activities in multiple cell types involved in postnatal vascular growth.  Therefore, 
we sought to determine the in vivo significance of osteopontin in this process.  To do so, 
we compared wild type and Osteopontin-/- mice for (1) their ability to form collateral 
vessels and functionally recover following acute induction of hind limb ischemia and (2) 
their capacity for neovascularization, mineralization, remodeling, and the restoration of 
mechanical properties during fracture healing.  Data suggested that OPN is a critical 
regulator of collateral vessel formation and that this effect is driven by its role in 
mediating monocyte/macrophage migration and functionality.  Secondly, we found that 
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the presence of osteopontin was essential for normal early callus formation, 
neovascularization, late stage callus remodeling, and restoration of biomechanical 
strength.  Abnormal collagen organization was observed within the remodeling fractures 
of Osteopontin-/- mice, and we hypothesize that a unifying link between the vascular and 
bone defects may be related to deficient matrix organization and remodeling.   
In conclusion, the imaging techniques developed in this thesis provide a novel 
methodology for quantitative analysis of vascular structures in small animal models.  
Secondly, this project has yielded an improved understanding of the basic 
pathophysiological mechanisms that control postnatal blood vessel growth and bone 







 Better understanding the mechanisms of postnatal vascular growth has clinical 
relevance in a myriad of applications including treatment of cardiovascular disease, 
cancer therapy, enhancing wound healing, and growth of engineered tissues.  For 
example, therapeutic stimulation of blood vessel growth could alleviate pathological 
conditions such as tissue ischemia caused by peripheral or coronary artery disease.  
Peripheral limb arterial occlusion, common in diabetic patients, causes formation of 
chronic skin ulcers and often requires limb amputation.  Myocardial ischemia is the 
leading cause of morbidity and mortality in the world (1), and it has traditionally been 
treated by coronary artery bypass surgery, a highly invasive procedure that often leaves 
ischemic areas in the cardiac tissue that are not amenable to revascularization.  In 
addition, accelerating wound repair and the success of many applications in the growing 
field of tissue engineering depend on an adequate blood supply in order to maximize 
cellular viability and functional tissue regeneration.   
 Our long-term goal is to further elucidate the biological processes of angiogenesis 
and collateral development and gain knowledge that can help to develop improved 
clinical strategies that will optimize vascular function in ischemic, injured, and 
engineered tissues.  To this end, we have investigated improved methods for quantifying 
vascular growth and utilized these methods to explore the potential role of osteopontin 
(OPN) in ischemic limb collateral development and in angiogenesis and healing of bone 
fractures.  OPN, a non-collagenous extracellular matrix protein, has recently been 
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suggested to play a role in the regulation of angiogenesis (2,3).  Based on these studies, 
the central hypothesis for this study was that OPN plays a physiologically relevant role in 
control of non-pathological, postnatal vascular growth in vivo.  The overall objective of 
this project was to utilize microcomputed tomography (micro-CT) imaging and a 
combination of in vivo and in vitro studies to develop new methods for quantification of 
blood vessel network morphology and to gain new insights into the role of OPN in blood 
vessel formation.  Our collaborative team, which possesses expertise in cardiovascular 
biology, vascular imaging, bone healing, tissue engineering, and biomechanics, has 
approached this objective through the following specific aims. 
Aim I 
Validate micro-CT imaging as a method for quantifying vascular network 
morphology.   
Our working hypothesis was that micro-CT imaging in combination with perfused 
contrast agents can provide a highly objective and quantitative method for analysis of 
three-dimensional (3-D) blood vessel architecture in small animal models.  To 
accomplish this aim, we utilized the previously characterized mouse hind limb ischemia 
model to provide a well-controlled environment for analyzing collateral vessel formation.  
We also completed sensitivity analyses on the effects of image voxel size and 
binarization threshold on micro-CT analyses.  Standard histology assessments were used 





Characterize the role of OPN in collateral development during hind limb ischemia. 
 Our working hypothesis was that OPN deficient mice would show a reduced 
capacity for collateral vessel formation compared to wild type controls.  We employed 
the hind limb ischemia model to evaluate the potential for neovessel formation in OPN-/- 
and wild type mice.  Quantitative, anatomical evaluations of collateral vessels were 
completed using the novel micro-CT techniques developed in Specific Aim I.  Laser 
Doppler perfusion imaging was used as a functional assessment of restoration of distal 
limb perfusion, and an exercise endurance test was utilized as a physiological 
examination of ischemic limb functional recovery.  Aortic ring and macrophage 
migration assays were employed to gain mechanistic insight into our findings.   
Aim III 
Define the effects of OPN on neovascularization, mineralization, and biomechanical 
properties of long bones during fracture healing. 
 Our working hypothesis was that OPN-/- mice would display reduced angiogenesis 
and altered healing in long bone fractures relative to wild type controls.  To test this 
hypothesis, a well-established femoral fracture healing model (4) was utilized to study 
the time course of fracture healing in wild type and OPN-/- mice.  Micro-CT, quantitative 
reverse transcription polymerase chain reaction (RT-PCR), and histology were used to 
evaluate vessel growth, matrix formation, and bone remodeling at the fracture site.  In 
addition, mechanical testing of fractured femurs was performed to test whether OPN 
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deficiency compromised the restoration of mechanical strength during the healing 
process.   
Innovation and Significance 
This work is innovative because it utilized 3-D micro-CT imaging for evaluating 
blood vessel growth within ischemic tissue and at sites of injury. In doing so, our group 
has developed a technique that is more quantitative and reproducible than the commonly 
used two-dimensional (2-D) histological analyses, laser Doppler perfusion imaging, or 
micro-angiography.  In addition, the available OPN knockout mouse colony provided a 
unique setting that allowed us to precisely determine the previously unknown role of 
OPN in the biological processes of collateral vessel formation and fracture healing.    
Successful angiogenic therapy requires temporal control, specificity to a targeted 
tissue, and avoidance of undesirable side effects associated with hypervascularity such as 
tumorigenesis and proliferative retinopathy.  Therefore, this work is significant because 
an improved understanding of the underlying biological mechanisms and the role of 
factors involved in vascular growth will aid in the development of safe and clinically 
effective treatment options.  This project has acquired a new understanding of postnatal 
vascular growth that could potentially be incorporated into development of new clinical 
treatments, and it has also provided a new platform methodology that can be applied for 
the screening of other pro- and anti-angiogenic factors in future studies.  In summary, this 
thesis project has yielded the following outcomes.  First, the imaging techniques 
developed are expected to become a standard for quantitative, volumetric analysis of 
neovascular responses in small animal models.  Secondly, application of these 
techniques, combined with the use of the available osteopontin deficient mouse colony, 
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has yielded an improved understanding of the basic pathophysiological mechanisms that 
control postnatal blood vessel growth and bone fracture healing.     
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
Postnatal Vascular Growth 
Vascular Anatomy and Accepted Modes of Postnatal Vascular Growth 
The basic constituents of normal blood vessels are endothelial cells, smooth 
muscle cells, fibroblasts and pericytes, basement membrane, and extracellular matrix (see 
Figure 2.1).  Postnatal blood vessel development is a complicated, incompletely 
understood process involving a complex cascade that includes a wide range of cell types, 
growth factors, extracellular matrix (ECM) proteins, cell surface receptors, and 
intracellular signaling pathways.  This process is relevant to pathological 
neovascularization in the setting of tumorigenesis, proliferative retinopathy, and 
rheumatoid arthritis, but it is also vital to formation of new vessels for restoration of 
normal blood perfusion to ischemic tissues.   
The three different mechanisms that have been hypothesized to contribute to 
formation of new vascular structures are arteriogenesis, angiogenesis, and vasculogenesis 
(see Figure 2.2).  Arteriogenesis occurs when preexisting arterioles dilate and remodel 
through endothelial and smooth muscle cell expansion to meet increased physiologic 
demands (5,6).  It is hypothesized that this process, which is mediated at least in part by 
monocytes and macrophages, is triggered by the increased shear stress that occurs in 
small, interarterial anastomoses following occlusion of a parent artery (7).  Angiogenesis 
involves sprouting or intussusception of new capillaries from pre-existing vessels and is 
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Figure 2.1.  Arterial Anatomy.  (A) Schematic and (B) histological image of a normal 
arterial wall cross-section. I = Intima:  endothelial cells on basement membrane.  A = 
Adventitia: fibroblasts, collagens, elastin, etc.  M = Media:  smooth muscle cells, collagens, 
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Figure 2.2.  Three modes of postnatal vascular growth that are thought to occur in vivo.  
(A) Arteriogenesis involves recruitment of pre-existing vessels to remodel and increase 
their blood flow capacity.  (B) Angiogenesis entails sprouting of new capillaries from 
existing vasculature.  (C) In vasculogenesis, or de novo vessel formation, bone marrow 
derived cells home to the sites of ischemia and participate in neovascularization. 
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within the lumen of a preexisting vessel, partitioning the remodeling vessel into two new 
capillaries.  Sprouting angiogenesis involves basement membrane degradation, 
endothelial cell migration toward angiogenic factors, endothelial cell proliferation, lumen 
formation, and vessel stabilization by basement membrane production and association 
with periendothelial cells (8).  Finally, there is evidence that vasculogenesis or de novo 
blood vessel formation by bone-marrow derived endothelial progenitor cells may play a 
role in postnatal vessel growth, although this remains controversial (9,10).  Arteriogenic 
recruitment of preexisting collaterals is widely believed to be the best means for 
reestablishing normoxia following arterial occlusion since it occurs relatively quickly and 
leads to formation of larger arteries that have higher blood flow capacity compared to 
nascent capillary structures (5). 
Control of Vascular Growth 
VEGF and FGF 
The majority of researchers studying treatments for ischemic disease have focused 
on the clinical potential of administering vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF) to enhance blood flow via new vessel formation.  This 
idea, termed therapeutic angiogenesis, has been applied for both myocardial ischemia and 
peripheral arterial disease.  Numerous efforts have been directed at testing the efficacy 
and safety of delivering these growth factors as recombinant proteins or via gene therapy 
for stimulation of angiogenesis and arteriogenesis in ischemic tissues.   
VEGF was first discovered over 20 years ago, when it was originally termed 
vascular permeability factor due to its inherent ability to promote vascular leakage (11-
13).  It is up regulated in response to ischemia (14) and serves as a well-known mediator 
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of both physiological and pathological angiogenesis through promotion of proliferation, 
survival, and migration in endothelial cells.    There is a 5-member family of VEGF 
proteins that includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth 
factor.  These factors act through three tyrosine kinase receptors (VEGFR-1, -2, -3) to 
activate downstream signaling pathways.  VEGF-A (commonly referred to as VEGF) has 
been the most researched as a potential therapeutic agent.  The importance of VEGF-A in 
vascular development is clearly illustrated by the fact that knocking out VEGF-A or 
either of its receptors (VEGFR-1 and VEGFR-2) results in embryonic lethality (15-17).  
Other growth factors, such as FGF, complement the angiogenic activity of VEGF, and 
there is likely considerable cross-talk between these factors (18).   
The FGF family consists of as many as 25 members which are named in 
consecutive order (FGF-1, -2, etc) (19).  The different FGF family members contain a 
highly preserved core amino acid sequence that leads to structural homogeneity between 
family members (20,21).  There is thought to be significant redundancy in the 
functionality of the FGF family members, as evidenced by the relatively mild phenotype 
that results in FGF-1, FGF-2, and even FGF-1 / FGF-2 double knockouts (22-24).  FGFs 
act on numerous cell types and are involved in a variety of biological effects including 
but not limited to development, cell proliferation and migration, wound healing, and 
tumorigenesis.  The effects are believed to be transmitted through FGF activation of 
signal transduction pathways via its family of 4 tyrosine kinase receptors (FGFR1-4) as 
reviewed by Powers and colleagues (25).  FGF-1 (acidic FGF) and FGF-2 (basic FGF) 
are the two best characterized family members and have been studied extensively for 
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their roles in angiogenesis.  Up to this point, clinical trials have focused on therapeutic 
potential of FGF-2 for stimulation of angiogenesis.       
Preclinical data from animal studies using both VEGF and FGF have shown 
tremendous promise in a variety of animal models (26-30).  However, many of the initial 
human clinical trials did not corroborate these results and have shown almost no 
improvement in clinical outcome.  The VIVA, RAVE, FIRST, and TRAFFIC trials are 
examples of the most prominent double-blind, placebo controlled trials to date.  The 
VIVA (Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis) trial 
was a double-blind, placebo-controlled study that found that delivery of recombinant 
VEGF produced mild improvement in angina but did not significantly affect other 
endpoints analyzed (31).  The RAVE (Regional Angiogenesis with Vascular Endothelial 
growth factor) trial, which tested adenoviral VEGF gene transfer for the treatment of 
peripheral artery disease, found no increase in exercise performance or quality of life as a 
result of treatment (32).   FIRST (FGF Initiating RevaScularization Trial) involved 
delivery of recombinant FGF-2 for treatment of coronary artery disease, which produced 
a trend towards decreased angina at 90 days but no improvement in exercise tolerance or 
myocardial perfusion (33).  Lastly, the TRAFFIC (Therapeutic Angiogenesis with 
Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication) trial found 
peripheral arterial disease to be modestly alleviated through delivery of recombinant 
FGF, which was found to increase peak walking time (34).  
Unfortunately, as mentioned, there have been a limited number of double blind, 
placebo controlled clinical trials to test therapeutic agents, and these studies have found 
only mildly promising results.  However, these trials have shown enough clinical 
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potential to warrant further investigation, and one could postulate that therapeutic 
angiogenesis may be a viable clinical option with the optimal growth factor, appropriate 
dosage, most effective delivery method (recombinant protein versus viral vector or naked 
DNA gene therapy), and location of delivery (intracoronary, intravenous, intramuscular, 
etc).  In addition, temporal considerations must be made, particularly in the case of acute 
myocardial infarction (AMI), in order to determine the ideal delivery protocol (time post-
AMI and single versus multiple treatments).  More research is clearly needed in multiple 
areas in order to find the optimal clinical protocol for delivery of pro-angiogenic 
treatments.  Also, it is imperative that scientists are able to define the roles of all factors 
involved in this process, and clinicians must carefully consider the roles of ECM 
mediators in addition to the potential synergistic effects from using combined growth 
factor therapies.  Hence, it is possible that, ultimately, the optimal treatment will contain 
a “cocktail” of therapeutic agents, which could potentially include not only growth 
factors, but also other “extracellular modulators” and progenitor or stem cells that may 
aid in vascular regeneration.   
The Role of ECM 
 The cellular components of the postnatal vascularization process are coordinated 
by direct cell-cell communication, paracrine and autocrine growth factor stimulation, and 
lastly, cues provided by the extracellular environment.  Type I collagen, laminin, 
fibronectin, vitronectin, and osteopontin are among the many ECM proteins thought to 
play a role in blood vessel formation and remodeling.  ECM components provide the 
structural scaffolding that maintains the organization of vascular cells into blood vessels 
and also initiate signals that stimulate specific cellular responses.  ECM generated signals 
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are primarily mediated through the integrin receptors and elicit events such as cellular 
survival, proliferation, and migration.  The integrins are heterodimeric transmembrane 
receptors that consist of the combination of one α and one β subunit.  There are 18 α and 
8 β subunits known to exist, and through different combinations of these subunits, about 
24 unique integrins are generated.  As reviewed by Serini et al., currently, nine of these 
integrins have been characterized for their implications in blood vessel formation (35).  In 
general, docking of these integrins to the ECM activates signaling pathways through 
integrin-associated kinases and other signaling molecules located on the intracellular side 
of the cell membrane.  These signaling pathways then propagate to the nucleus to alter 
gene expression and trigger a subsequent cellular response. 
 ECM proteins are able to induce specific cellular responses based upon the 
integrin(s) that they bind.  For example, collagen and fibronectin are thought to act 
through α1β1, α2β1, α5β1, and αvβ3 to activate endothelial cells and promote proliferation 
and tube formation, while laminin rich matrices promote endothelial stabilization and 
maturation through α6β1 and α3β1 (36).  In this sense, it is thought that the multiplicity of 
proteins in the ECM is able to function cooperatively to orchestrate the appropriate cell 
signals.  However, based on the large degree of functional overlap, it is impossible to 
assign clearly defined roles to each ECM and integrin constituent.  For instance, αvβ3, 
one of the most extensively studied angiogenesis-related integrins, binds specifically to 
the arginine-glycine-aspartate (RGD) motif, a peptide sequence common to a number of 
ECM proteins including collagen, fibronectin, vitronectin, and osteopontin.  Through 
these overlapping pathways, it is possible for the same integrin to convey different 
signals depending upon its mode of activation and the surrounding biological milieu.   
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The integrin(s) that control the ECM signaling pathways also depend upon the 
cell’s activation by other factors.  For example, studies have shown that the αvβ3 
signaling dominates during FGF induced angiogenesis, while αvβ5 dictates VEGF 
induced angiogenesis (37).  Other modes of cross talk are also thought to exist between 
the ECM and other angiogenic factors.  For instance, VEGF induces endothelial 
expression of α1β1 and α2β1, sensitizing these cells to ECM effects (38).  Furthermore, 
the ECM is thought to immobilize growth factors to the matrix in order to make them 
readily available to cellular receptors and to provide directional cues to the intracellular 
migratory machinery.  One example of this paradigm is illustrated by a study that showed 
that VEGF binds directly to fibronectin in a way that enables them to serve as signaling 
cofactors in the angiogenesis process (39).  It is obvious that ECM-integrin signaling 
represents an intricate system that plays a significant role in postnatal vascularization.  
While much knowledge has been garnered on the regulation of neovascularization at this 
level, there is clearly a lot left to learn about the complexities of this system, including its 
interrelationship with other growth factors and cellular activities that control vascular 
growth. 
The Role of Monoctyes / Macrophages 
 Although macrophages are not thought to be a substantial constituent of normal, 
healthy vasculature, it is well-known that they localize to the vascular wall at sites of 
angiogenesis and arteriogenesis where they play an important role in modulation of these 
processes (6).  Wolfgang Schaper has been a leader in this field and has extensively 
studied the role of these cells in models of ischemia since his initial observations of 
monocyte homing to the inner vascular surfaces of forming collateral vessels in a model 
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of coronary artery stenosis in dogs (40).  It was only shortly after this publication that 
activated macrophages were reported to also play a role in angiogenesis (41).  Subsequent 
studies have shown a direct functional link between circulating monocyte concentration 
and arteriogenic collateral vessel formation (42,43). 
Monocyte Chemotactic Protein 1 (MCP-1) is thought to be the primary stimulus 
for induction of monocyte infiltration and is known to play a role in mediating 
inflammatory related neovascularization (44).  Treatment with VEGF and FGF-2 has 
been found to induce MCP-1 expression in endothelial cells indicating crosstalk between 
MCP-1 and other angiogenic growth factors (45,46).  To further support this hypothesis, 
delivery of MCP-1 has been shown to accelerate collateralization and recovery in hind 
limb ischemia models in a wide range of rabbit, pig, and mouse studies (47-53).   
Conversely, animals deficient in MCP-1 or CCR2-chemokine receptor, an MCP-1 
receptor, have been shown to display reduced monocyte / macrophage infiltration and 
collateral formation (54,55).  These studies indicate that, once they home to the vascular 
wall, monocytes produce growth factors and proteases that induce vascular endothelial 
and smooth muscle cell proliferation and stimulate remodeling of the vascular wall in 
order to satisfy increased blood flow demands.  Taken together, these reports have 
convincingly shown that monocytes play an important role in mediating collateral vessel 
formation and that stimulating monocyte homing and survival at sites of arteriogenesis 
enhances collateral blood vessel formation.   
Endothelial Progenitor Cells 
  Nearly 10 years ago, Asahara and colleagues first isolated circulating endothelial 
progenitor cells (EPCs) from peripheral blood and showed that these cells were capable 
 16
of homing to sites of ischemia and incorporating into angiogenic vasculature (56).  
Shortly thereafter, using bone marrow transplantation techniques, Asahara et al. and Shi 
et al. reported that these circulating EPCs were mobilized from bone marrow and were 
capable of endogenously incorporating into angiogenic vasculature in skin wounds, sites 
of peripheral and myocardial ischemia, and developing tumors, in addition to lining the 
flow surfaces of implanted vascular grafts (9,57).  These discoveries spurred a rapid 
expansion in EPC research, which has created a plethora of generally positive, yet 
controversial data due to the lack of standardized cell isolation protocols and functional 
assays in this nascent field.  
 Since the inception of EPC research, numerous animal studies have been 
performed in multiple species to measure the regenerative and reparative potential of 
EPCs.  These studies have generally shown accelerated recovery following EPC delivery 
in animal models of myocardial and peripheral ischemia (reviewed in (58)).  Many of 
these authors have reported direct incorporation (albeit to varied degrees) of transplanted 
progenitor cells into the vascular endothelium in vivo using angiogenesis models of hind 
limb, myocardial, and cerebral ischemia and tumorigenesis (59-65).  However, this 
notion has been increasingly challenged.  Some recent studies have claimed that few or 
no EPCs actually incorporate into the endothelium, leading to the idea that the angiogenic 
effects of these progenitors may be primarily due to paracrine stimulation of tissue 
resident cells (66-71). 
 Human studies have further indicated that EPCs play a role in general endothelial 
maintenance and possess the potential to stimulate therapeutic angiogenesis and 
accelerate recovery following myocardial infarction.  It has been reported that EPC 
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counts serve as a potential marker of endothelial function and are inversely proportional 
to cardiovascular risk (72-74).  Likewise, diabetes, smoking and hypercholesterolaemia   
have been shown to decrease EPC counts, while statin therapy and regular exercise have 
been found to increase EPC number (73,75-80).  In terms of therapeutic angiogenesis, the 
TOPCARE-AMI (Transplantation of Progenitor Cells And Regeneration Enhancement in 
Acute Myocardial Infarction) study investigated effects of both circulating EPC and bone 
marrow derived progenitor infusion following AMI.  In this relatively small trial, safety 
and favorable effects on left ventricle (LV) remodeling were found following infusion of 
both progenitor cell types (81).  In a similar AMI trial, autologous bone marrow was 
found to lead to improved LV function relative to controls (82).   
One major shortcoming in the field of EPC research has been the inconsistent 
definition of the EPC itself.  Several animal studies have utilized unpurified bone 
marrow, which likely contains EPCs in addition to other progenitor cells.  Others have 
used magnetic bead or fluorescence activated cell sorting to obtain enriched cell 
populations based on co-uptake of acetylated ldl / lectin or expression of surface markers 
such as VEGFR2, CD31, CD45, CD105, CD133, Sca1, vWF, and VE-cadherin, with the 
most commonly used technique being isolation based on VEGFR2, CD31, and/or CD133 
expression.  It remains unclear whether different cell selection methodologies yield 
different cell populations or the same cell population at different stages of maturity, and it 
has not been clearly determined which if any of these populations might possess the 
greatest therapeutic potential.  Unfortunately, this lack of a consistent EPC definition and 
isolation protocol makes it difficult to draw conclusions based on direct comparisons 
between studies.  Clearly, many questions and controversy over EPC biology remain to 
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be resolved.  However, these cells undoubtedly possess great therapeutic potential, and 
preliminary success in animal and human trials demands further investigation and design 
of larger clinical trials.  
Inhibition of Neovascularization 
While the discussion up to this point has primarily focused on factors that 
stimulate neovascularization, excessive angiogenesis is believed to exacerbate certain 
pathological conditions including tumorigenesis, rheumatoid arthritis, and intraocular 
neovascular syndromes.  In this context, research has concentrated on inhibition of 
neovascularization.  It has been 35 years since Folkman originally proposed the idea that 
inhibition of angiogenesis could serve as a means for stopping tumor growth (83).  Then, 
in 1993 it was shown that VEGF neutralizing antibodies significantly attenuate tumor 
angiogenesis and growth in vivo, but it wasn’t until over ten years later that FDA 
approval was granted for the first anti-angiogenic agent for cancer therapy, bevacizumab 
(Avastin; Genentech) (84,85).  While bevacizumab is a neutralizing VEGF monoclonal 
antibody, many other approaches including but not limited to inhibiting VEGF receptor 
activation and administering soluble VEGF receptor or “VEGF traps” have been found to 
be effective means for anti-cancer therapy and are currently undergoing clinical tests 
(reviewed in (86,87)).  Meanwhile, analogous approaches for inhibition of 
neovascularization have also shown merit for treatment of macular degeneration and are 
being used clinically (88-90).  In addition to antagonism of VEGF signaling, other 
methods of angiosuppression are being tested clinically including exogenous delivery of 
naturally occurring angiogenesis inhibitors, inhibitors of proteases that facilitate ECM 
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degradation and vascular sprouting, and inhibitors of endothelial integrin (i.e. αvβ3) 
binding and activation (91-93). 
Experimental Models and Endpoints for Studying Angiogenesis 
With the recent expansion in research related to control of postnatal vascular 
growth, the requirement for quantitative, physiologically relevant models for preclinical 
studies has become increasingly apparent.  Although in vitro studies can serve as a useful 
initial screening tool for potential stimulants or inhibitors of endothelial cell function and 
growth, their relevance is often compromised by the fact that they lack the inherent 
complexity and milieu of cell types and factors present in vivo.  On the other hand, in 
vivo animal models obviously present the most appropriate systems for testing angiogenic 
substances, yet they often lack reproducibility due to technical difficulty and variability 
between animals, physiologically relevant stimuli, and endpoints amenable to 
quantitative analysis.  The subsequent discussion on in vitro and in vivo techniques 
covers some of the common and most relevant angiogenesis models but is by no means 
meant to be all-inclusive.    
Cell proliferation, migration, and tube formation in response to specific 
angiogenic modulators comprise the majority of in vitro studies.  Cell proliferation 
studies typically measure replicating cells through incorporation of a fluorescent or 
radiolabeled thymidine analogue or quantification of total cell number using colorimetric 
/ fluorescent readings based on dye-DNA complexes.  Migration and chemotaxis assays 
typically employ cell culture inserts that can be placed into multi-well tissue culture 
plates.  The cells are seeded into these inserts, which contain a membrane with a pore size 
ranging from approximately 3-10 microns.  Then, the chemotactic agent is placed into the 
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media in the bottom of the well in order to stimulate cell migration from the top of the 
membrane into the lower chamber containing the chemotactic substance.  Lastly, at a 
chosen endpoint, the remaining cells can be removed from the top of the membrane, and 
the cells that have migrated to the lower side are stained and counted using microscopy.  
The monolayer scratch assay provides a separate and somewhat crude, but effective 
migration assay.  This technique involves creation of a “wound” in the endothelial 
monolayer using a pipette tip and then monitoring migration (and proliferation if the 
endpoint is long enough) of the cells into the scratch.  Lastly, endothelial cells can be 
cultured in 3-D in matrigel to assess tube-forming capabilities of endothelial cells under 
specific stimuli.  Each of these in vitro methodologies possesses merit in certain 
applications, particularly as an initial platform for screening the effects of potentially pro- 
or anti-angiogenic substances.  These assays are well controlled, repeatable, and 
generally quantitative, yet their relevance can be limited by the absence of many of the 
important modulators present in vivo.  One problem is that, due to repeating tissue culture 
passaging, cells are selected for a more proliferative phenotype than what is present in 
vivo.  Also, cells are often isolated from a species (i.e. bovine) and from an anatomical 
location (ie. vein or large arteries such as aorta) that don’t necessarily make them good 
models of the human microvascular endothelium that would typically participate in an 
angiogenic response. 
As an intermediate to in vitro and in vivo studies, researchers commonly use ex 
vivo organ culture assays.  The most common of these is the aortic ring vascular 
sprouting assay.  This assay involves embedding aortic rings into either collagen gels or 
fibrin clot and has been utilized in explants from both mice and rats.  Rat explants have 
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been found to sprout endothelial tubes in serum free conditions, while mouse specimens 
require homologous serum in order to consistently form angiogenic extensions from the 
aortae (94-96). This assay provides a more complete environment including non-
endothelial cell types, lacks artifacts introduced from extended tissue culture passaging, 
yet offers a good deal of the experimental control afforded by in vitro studies.  However, 
as mentioned for in vitro studies, use of the aorta is not an ideal choice for modeling the 
microvascular endothelium.  
Following initial screening tests based on in vitro and / or ex vivo studies, animal 
experimentation is a necessity prior to testing potential angiogenic modulators in human 
trials.  The chick chorioallantoic membrane (CAM) is one of the oldest, simplest, and 
most popular in vivo angiogenesis assays (97,98).  It is generally considered an in vivo 
assay because it is a test carried out on a whole animal (embryo).  In this assay, an 
angiogenic substrate is placed directly onto the CAM and then tested for its ability to 
either inhibit or increase vascular development in this area of the embryo.  This assay is 
relatively easy, inexpensive, and high throughput, but doesn’t provide maximum utility 
due to its use of chick cells, lack of quantification, and difficulty in discriminating 
between effects of the tested agent and the rapid vascular changes that are naturally 
occurring during embryonic development.   
The next group of commonly employed in vivo angiogenesis models involves 
subcutaneous placement of angiogenic substrates.  These types of models involve 
implantation of a sponge or matrigel plug under the dorsal skin to induce neovascular 
ingrowth (99-102).  This model also allows for delivery of angiogenic modulators, which 
can be done using osmotic mini-pumps.  This procedure is simple and easy to replicate, 
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but it does not use a site where angiogenesis typically occurs in vivo and is confounded 
by the non-specific inflammatory response the results from implantation of the material. 
Corneal angiogenesis assays are another popular mechanism for in vivo screening 
of angiogenesis related compounds.  The cornea is naturally avascular and therefore 
provides a good test bed for neovascularization studies, and this model has been used in 
multiple species including rabbits and mice (103-106).  In this method, a small pocket is 
made in the cornea, and slow release formulations of angiogenic factors or tumor 
cells/tissue can be introduced into this pocket in order to induce vascular growth toward 
this stimulus.  For testing anti-angiogenic therapies, the therapeutic agent is generally 
administered systemically and tested for its ability to inhibit angiogenesis towards the 
pro-angiogenic corneal implant.  Neovascularization can be tracked longitudinally in vivo 
using a stereoscope or with histology at predetermined endpoints.   The main advantage 
of this assay is that all measurable vasculature is neoangiogenic in nature and does not 
have to be discriminated from preexisting vessels.  However, this assay is technically 
demanding, and the fact that angiogenesis does not normally occur in avascular regions in 
vivo diminishes the assay’s relevance. 
The last set of models to be discussed involves ischemia and arterial blockage 
induced vascular growth.  These animal studies have been performed in a variety of 
species, particularly rats, rabbits, and mice, and typically test the effects of agents for 
therapeutic stimulation of neovascularization for alleviation of peripheral or coronary 
artery disease (107-110).  These models involve ligation of a proximal conduit artery (ie. 
femoral artery), which provides a reproducible, physiologically relevant stimulus for a 
vascular response.  This insult stimulates a combination of ischemia-induced 
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angiogenesis in addition to arteriogenesis triggered by changes in arterial flow patterns 
within the preexisting vasculature.  This complex stimulus is likely the most relevant 
model of human ischemic diseases, but offers the added problem of discriminating 
neoangiogenic and arteriogenic vessels from each other and from the preexisting 
vasculature.  In addition, this model is time intensive and relatively expensive due to the 
number of animals necessary to detect differences due to inherent animal-to-animal 
variability and lack of sensitive methods for endpoint quantification.  This model is also 
particularly useful for studies of transgenic or knockout animals since it can be readily 
applied to mice (107).  When considering methods for inducing tissue ischemia versus 
the previously discussed models, one must consider the different levels of complexity and 
potential merit of each model depending upon the setting being studied (pro- versus anti-
angiogenic therapy) and the available resources.     
As mentioned, in addition to inherent animal-to-animal variability and user 
variability due to technical difficulty in implementation of animal models, in vivo studies 
are further complicated by lack of objective, quantitative methods for endpoint analysis.  
It is generally understood that collateral vessel formation can help to functionally 
compensate for obstructive vascular lesions in patients with atherosclerosis and that 
animal models of vessel blockage are vital to preclinical research that tests the efficacy 
and safety of therapeutic agents delivered to stimulate reperfusion of ischemic tissues.  
While the utility of the hind limb ischemia model is particularly well established in this 
arena, the available methodologies for quantification of collateral vessel development in 
this setting are not ideal.   
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Investigators have utilized a variety of techniques to evaluate vascular structures 
in this animal model.  Histology is commonly employed to analyze capillary or arteriole 
density, but it is relatively subjective, not truly quantitative, two-dimensional (2-D), and 
not necessarily representative of vascularity throughout the entire sample.  Laser Doppler 
perfusion imaging (LDPI) has been used to analyze blood flow in hind limbs because it 
offers quantitative data and a good measure of tissue perfusion (5,107,111-113).  
However, this technique does not provide anatomical information and is limited by the 
fact that only the most superficial, cutaneous blood flow is measured.  Another popular 
technique, X-ray microangiography, provides high-resolution, 2-D angiograms of the 
hind limb vascular anatomy but lacks the ability to employ a quantitative, volumetric 
analysis (113-115).  Injection of colored or fluorescent microspheres presents a method 
for longitudinal study of reconstitution of perfusion to ischemic tissues using quantitative 
spectrophotometry or flow cytometry analyses (116-120).  However, the required arterial 
catheterization or injection of microspheres into the left ventricle or atrium presents a 
considerable challenge in mice because of their small size.  Other imaging modalities 
such as magnetic resonance angiography and positron emission tomography serve as 
viable methods for analyzing vascularity, but the resolution of these methods is typically 
not sufficient for studies involving small animals.  Micro-CT has emerged as a promising 
technology that can overcome several of the challenges associated with evaluation of 
vascular networks.  Recently, vascular imaging procedures have been developed for 
small animal models based on the use of perfused contrast agents and X-ray micro-CT 
(121-129).  The goal of these studies has been to visualize 3-D vascular networks in 
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organs (i.e. heart and kidneys) or tumors, and more recently, we have extended these 
techniques into analysis of neovascularization and collateral vessel development (130).   
Micro-CT Imaging 
Hounsfield originally introduced computed tomography in the early 1970’s, an 
invention that eventually earned him a Nobel prize (131,132).  In the late 1980’s, 
Feldkamp et al. pioneered the field of three-dimensional computed tomography on the 
micron scale (micro-CT) for analysis of bone micro-architecture (133).  Since then, the 
field of micro-CT has advanced tremendously, and commercially available micro-CT 
systems have become a major component of many research laboratories.  These systems 
combine a microfocus X-ray source, a detector, and a cone-beam reconstruction 
algorithm to nondestructively recreate a 3-D object (see Figure 2.3 A).  Using this setup, 
the specimen is rotated on a fixed stage while an X-ray source is passed through it.  
However, newer generation scanners exist that allow for in vivo scanning of anesthetized 
animals.  In these systems, the animal remains stationary and the x-ray source and 
detector rotate around the specimen.  The detector then records the intensity of the 
attenuated X-ray beam that has passed through the specimen.  This projection value 
recorded by the detector is a function of the thickness and linear attenuation coefficient of 
the material through which the X-ray beam has passed.  This relationship can be 
described by Lambert’s law of absorption where I is the recorded beam intensity after 
passing through the specimen, Io is the unattenuated beam density, µ is the linear 
attenuation coefficient of the material within the sample, and x is the thickness of the 
material. 
Equation 2.1.    xoeII
µ−=  
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Based on the intensity of the X-ray projections recorded as the specimen (or 
source) is advanced through multiple rotational positions, serial, two-dimensional 
attenuation maps (tomograms or slices) are reconstructed from the raw data using a cone 
beam filtered backprojection algorithm (see Figure 2.3 B) (134).  During the 
reconstruction of image projections, a grayscale value that represents the capacity of the 
material within that space to attenuate x-rays is assigned to each voxel.  These grayscale 
values within the 2-D slices represent the linear attenuation coefficient of the material 
within the voxel space, which is a function of the X-ray source and the atomic 
composition of the material sample.  Then an image threshold is defined, which 
represents the cutoff grayscale (attenuation) value that partitions the image voxels into 
either the background or the segmented object.  During the thresholding process, if the 
grayscale value for the voxel is higher than the assigned threshold, it remains in the 3-D 
image as part of the segmented object.  After application of the global attenuation 
threshold value, the binarized tomograms are used to render a 3-D image of the 
segmented object.  Morphometric analysis based on model independent, direct distance 
transform methods can be subsequently applied to the 3-D images to quantify parameters 
of morphology, anisotropy, and connectivity (135-137). 
As mentioned, due to the inherent radiodensity of hard tissue, initial micro-CT 
related work was done in the bone field.  However, more recent applications in micro-CT 
imaging have evolved into analysis of biomaterials, soft tissues, and skeletal development 
(138,139).   However, due to the comparatively low radiodensity of soft tissues and 
vasculature, application of a radiopaque contrast agent is necessary.  For these 
applications and countless others not mentioned here, micro-CT presents many 
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advantages over other, traditional methods of specimen imaging and analysis.  Since the 
imaging process is nondestructive, the internal features of the same sample may be 
examined multiple times, and samples remain available after scanning for additional 
biological or mechanical testing.  Specifically, micro-CT is often advantageous over 
other methods because it provides high resolution, quantitative, 3-D, and completely 
objective data analysis.  Relative to micro-CT, histology and microscopy, the traditional 
standards in tissue specimen analysis, require destructive tissue processing, lack the 
ability to employ a quantitative 3D analysis, and require increased sample preparation 







Figure 2.3.  Micro-CT Components and Image Reconstruction.  (A) Schematic view of 
the basic components of micro-CT  imaging systems.  An X-ray source is passed through 
a rotating specimen, and the transmitted signal is detected on the other side.  (B)  
Schematic of the computed tomography process and illustration of the method for 
reconstruction of micro-CT images from X-ray projections (borrowed from (140)). 
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Bone Fracture Healing 
Unlike soft tissue injuries, which generally result in scar tissue formation, bone 
healing involves regeneration of the native tissue in a unique process where the original 
tissue properties are largely restored.  The capacity for true tissue regeneration in adults is 
thought to be due to the fact that fracture repair to a large degree recapitulates the process 
of embryonic skeletal formation (141).  The majority of bone fracture healing cases 
involve both intramembranous (direct bone formation) and endochondral ossification 
(bone formation through a cartilage intermediate).  Rarely does primary bone healing 
occur through an intramembranous ossification route, and this is thought to occur only 
when contact is restored and rigidly fixated between fractured bone ends (142).  
Conversely, the endochondral route of bone repair is thought to dominate in less 
stabilized fractures, and it is this process that closely resembles fetal endochondral 
ossification (141,143).   
The majority of bone healing occurs through indirect fracture healing, which 
involves a combination of intramembranous and endochondral ossification.  This 
involves a highly coordinated cascade of biological events that includes, in temporal 
order, hematoma formation, inflammation, soft cartilaginous callus formation, 
neovascularization, osteoblastic callus mineralization, and osteoclastic remodeling of the 
woven bone hard callus into lamellar bone (144).  The morphological changes that occur 
during fracture healing are highlighted in the histology images shown in Fig 2.4.  This 
cascade of events is orchestrated by a variety of cell types, starting with bone marrow, 
periosteal, and tissue resident cells which subsequently chemoattract or differentiate into 










Figure 2.4.  Histological time course of fracture healing.  H&E staining of 5 micron 
paraffin embedded histological sections is shown to illustrate the time course of fracture 
healing in a mouse femoral fracture model.  Note that surrounding soft tissues were left 
intact on the 3-day histological specimen, but the fracture callus was dissected away from 
the surrounding musculature at other time points.  (A) At 3 days post fracture, inflammatory 
cells have migrated to the fracture site and produced cytokines that induce MSC migration, 
proliferation, and formation of an initial layer of fibrous connective tissue for stabilization 
of the fracture site.  (B) By 7 days post fracture, endochondral ossification has ensued, as 
indicated by the proliferation and differentiation of MSCs into a cartilaginous soft tissue 
callus at the fracture site.  Note that a modest amount of intramembranous bone formation 
can be seen at the periosteal region of the cortex immediately adjacent to the fracture site.  
Also, neovascularization, while not evident in these images, has begun to occur at the ends 
of the fracture callus.  (C) Later, by 14 days post fracture, chondrocyte hypertrophy is 
evident within the remaining soft fracture callus, and cartilage adjacent to the fracture has 
begun to mineralize and undergo resorption.  At this point a substantial amount of vascular 
invasion has occurred, which is thought to be directly coupled to onset of mineralization 
and chondrocyte removal from the soft callus.  (D) By 28 days, the mineralized cartilage 
has been replaced by remodeling woven bone, and a bony bridge has formed across the 
fracture gap.  (E) At 56 days, the woven bone of the fracture callus has remodeled inward, 




and osteocytes.  During this complex sequence of biological activity, functionality of 
these cell types is regulated by a variety of cytokines, growth factors, and matricellular 
proteins that induce differentiation, chemotaxis, and haptotaxis of the cell types 
responsible for mediating these events. 
Recent studies have helped to elucidate the roles of many of these signaling 
molecules in bone healing.  In initial stages of healing, pro-inflammatory cytokines such 
as interleukin-1 and tumor necrosis factor-alpha have been found to be highly expressed 
by inflammatory cells and are thought to play an important role in initiating the repair 
process by stimulating chemotaxis and proliferation of other cell types at the fracture site 
(145,146).  Other studies have detailed the importance of soluble growth and 
differentiation factors during fracture healing.  For example, the family of bone 
morphogenic proteins (BMPs), a subset of the transforming growth factor-beta 
superfamily, has been thoroughly characterized for induction of osteogenesis at fracture 
sites and is utilized clinically to promote bone regeneration (147).  The BMPs, which 
bind extracellular receptors and activate intracellular signaling cascades, are thought to be 
the key regulators of bone formation and have also been characterized for their ability to 
couple the biological processes of angiogenesis and bone formation (148-150).  This 
coupling is particularly important considering that vascular invasion of the fracture callus 
is thought to be a necessity for normal bone repair, specifically for triggering conversion 
of the cartilage callus into the mineralized, hard callus.  For example, Street et al have 
shown that VEGF, a known promoter of angiogenesis, stimulates neovascularization and 
promotes fracture healing, while treatment with angiogenesis inhibitors that specifically 
target vascular cells blocks fracture healing and produces atrophic nonunions (151,152).    
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Furthermore, it has been shown that fracture repair is impaired in MMP9 deficient mice 
as a result of reduced angiogenic capacity in these mice (153).  Lastly, ECM proteins 
play an important role in regulation of bone healing.  As reviewed by Alford et al., 
extracellular matrix (ECM) proteins, while not always vital for normal embryonic bone 
development, play an important role in mediating cellular function and serve as important 
modulators of bone regeneration (154).  Non-collagenous ECM proteins interact with 
other matrix proteins, cellular receptors such as integrins, and soluble growth factors and 
proteases.  In this way, they play a role in modulation of matrix organization and 
remodeling, cellular function, and hence, the fracture healing process.  Further 
understanding of the intricate interplay between this diverse set of cell types, endogenous 
factors, and matrix proteins is a necessity for the development of improved therapeutic 
strategies for promoting bone repair. 
Osteopontin 
OPN Structure and Function 
OPN, generally an ECM protein, is synthesized as a 34-kDa protein and is 
especially prominent in the matrix of mineralized tissues (see Figure 2.5 for an 
illustration of some of the features of OPN).  It undergoes a large degree of post-
translational modification and, depending upon tissue type, is secreted with varied 
degrees of phosphorylation and glycosylation.  It also binds to hydroxyapatite, contains a 
thrombin cleavage site, and, due to its acidic nature and negative charge, binds to 
calcium.   In addition, OPN possesses multiple cell recognition motifs and functions in a 
variety of biological processes including but not limited to inflammatory response, 
immunity, angiogenesis, wound  repair, tumor  formation  and  metastasis,  cell  adhesion, 
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Figure 2.5.  Schematic of human OPN.  The structure shown here highlights the binding 
domains of OPN that are thought to confer its biological activity.  O-glycosylation and 
phosphorylation sites are meant to be representative and can vary depending upon tissue 
localization, etc.  Schematic redrawn and adapted from (155). 
 
 
cell migration, and bone mineralization and remodeling.  Through its multiple cellular 
binding sites, OPN is able to interact with multiple cell surface receptors and activate 
intracellular activity that elicits downstream cellular functions.  While OPN is generally 
considered to fall into the general group of “noncollagenous ECM proteins”, it has more 
recently become known by some as a matricellular protein (156).  This categorization has 
been created for nonfibrillar ECM proteins that mediate cellular functions by providing a 
functional link between cell surface receptors, ECM molecules that are primarily 
structural in form, and more biologically active cytokines, growth factors, and proteases.  
By these means, it is likely that OPN is capable of eliciting a diversity of specified 
biological responses based on local content of the structural matrix, availability of 
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bioactive molecules, interactions with different cell types or surface receptors, and its 
own state of cleavage, phosphorylation, and glycosylation.    
OPN Cellular Interactions 
The integrin family and CD44 (hyaluronic acid receptor) are the two classes of 
cell surface receptors known to interact with OPN.  As mentioned previously, integrin-
mediated signals provide a vital link between the cells and their environment and 
represent an important point of control in the neovascularization process.  OPN 
interaction with heterodimeric integrin receptors is not only able to mediate cellular 
adhesion to the matrix, but also activate intracellular second messengers, which 
propagate signals to the nucleus and alter gene expression.  The integrin receptors known 
to interact with OPN include αvβ1, αvβ3, αvβ5, α4β1, α5β1, α8β1, and α9β1.  The majority of 
these interactions occur through the RGD site, a common three amino acid recognition 
sequence found in OPN and other ECM proteins, except for α4β1 and α9β1, which interact 
with a more novel serine-valine-valine-tyrosine-glycine-leucine-arginine (SVVYGLR) 
binding sequence (155,157-161).  The interaction of OPN with many of these integrins is 
regulated by thrombin cleavage, which is thought to increase accessibility of cell 
receptors to their binding domains and greatly enhance the cellular effects of OPN in 
many cases (162).  Different integrins respond differently to the full length versus 
cleavage fragments, indicating that this represents a key point of regulation of OPN 
function.  For example, while α5β1 reacts with the RGD sequence and α9β1 with 
SVVYGLR, both of these integrins are believed to only interact with OPN cleavage 
fragments and not the full length protein (159,161).  In addition, while the SVVYGLR 
fragment, which is located between the RGD and thrombin cleavage sites, can only be 
 34
bound by α9β1 following cleavage, α4β1 is able to interact with OPN before and after 
cleavage (158,161).  Integrin-OPN interactions can also be cell specific.  For example, 
αvβ3 adhesion of B lymphocytes to the RGD site of OPN is greatly enhanced following 
thrombin cleavage, but αvβ3 platelet adhesion to OPN’s RGD motif is no different in full 
length versus cleaved OPN (163).  It is this cell specific control of binding to a 
multiplicity of integrin receptors that likely affords OPN the ability to convey a diversity 
of signals to multiple cell types. 
 The other commonly studied OPN receptor, CD44, is a cell surface glycoprotein 
involved in cell-to-cell interactions, in addition to cell adhesion and migration.  Its 
principal ligand is considered to be hyaluronic acid, but it also binds to other ECM 
proteins such as OPN, fibronectin, collagen, and laminin.  Alternative splicing into 
functionally distinct isoforms are thought to confer the multifunctionality of CD44 (164).  
Weber et. al  initially reported the CD44-OPN receptor-ligand interaction and postulated 
that this relationship may be important for induction of cellular chemotaxis during 
metastatic tumor cell invasion (165).  Later, it was found that different splice variants of 
CD44 can interact with multiple domains on both the amino- and carboxy-terminal 
portions of OPN independent of the RGD motif in order to stimulate cell motility and 
chemotaxis (166).  More recently, Zohar and colleagues determined that the interaction of 
CD44 and other molecules with an intracellular, unsecreted form of OPN (iOPN) is an 
integral component in cell migration of multiple cell types including embryonic 
fibroblasts, activated macrophages, and metastatic cells (167).   
 As mentioned, OPN acts through these receptors primarily to control cell 
adhesion, migration, and chemotaxis.  Studying the role of these interactions in 
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tumorigenesis, inflammation, and wound repair have all been well-represented areas of 
research.  In the cancer field, OPN is thought to be related to both tumorigenesis and 
metastasis, and it was long ago found to be a secreted by transformed cells in culture 
(168).  As reviewed by Rittling and authors, numerous studies have reported that 
increased OPN expression in tumors and in the blood correlate with advanced 
tumorigenesis and metastasis, but its mechanistic role in cancer remains unclear (169).  
OPN has also been described for its role in immune and inflammatory responses.  It is 
expressed in response to inflammatory cytokines, serves as a chemoattractant to 
macrophages, and plays a role in immune response to viral and bacterial infection (155).  
The effects of OPN on macrophage function are likely a contributing factor to the larger 
role that OPN plays in tissue remodeling and wound repair.  In fact, upon the initial 
development of the OPN knockout mouse, the primary phenotype of these animals was 
reported by Liaw et al. to be diminished macrophage activity and matrix reorganization 
following skin injury (170).  It is noteworthy that some very recent studies have indicated 
that OPN plays a role in regulation of the stem cell niche and progenitor mobilization 
from the bone marrow, but the physiological relevance of this finding remains to be seen 
(171,172).  While OPN has implications in these and other normal and pathological 
processes, the properties of OPN relevant to postnatal vascular growth and bone fracture 
healing are of primary interest to this thesis.  
Vascular Functions of OPN  
While many researchers initially studied OPN for its role in bone, it is also 
important for normal arterial physiology (173) and is produced by all of the primary cell 
types involved in blood vessel growth and remodeling: monocytes/macrophages, 
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endothelial cells, and smooth muscle cells (174).  Previously reported in vitro studies 
have demonstrated that vascular cell interactions with OPN mediated through cell surface 
integrins regulate a wide variety of cellular functions that are potentially important to 
angiogenesis and arteriogenesis.  For example, OPN signaling through the αvβ3 integrin 
has been found to mediate endothelial cell survival in a process that involves the NF-κB 
signaling pathway (175).  Also, the angiogenic growth factor VEGF has been shown to 
trigger an increase in αvβ3 expression, OPN expression, and thrombin cleavage of OPN, 
which provides a cooperative mechanism that triggers a tremendous enhancement of 
endothelial cell migration (176).  In addition, OPN expression is induced by stimulation 
with FGF, and this cross-talk may provide a mechanism for recruitment of monocytes 
and amplification of FGF-induced angiogenesis (177).  Also, OPN mediates several 
processes relevant to arteriogenic collateral vessel formation including adhesion and 
migration of both macrophages and smooth muscle cells. (178-180).   
Several studies have also suggested an in vivo role for OPN in neovascularization.  
For example, OPN has been associated with the angiogenesis-related processes of tumor 
growth and metastasis in lung, breast, bone, and other tissues, indicating an active role of 
this protein in blood vessel growth (181-185).  Another recent study showed that OPN 
mRNA is locally upregulated at the site of ischemia induced retinal neovascularization in 
mice (3).   Also, in a study on the role of OPN in mediating osteoclast function, OPN 
deficient mice were found to display decreased resorption of ectopic bone implants, an 
effect the authors hypothesized to be secondary to reduced angiogenesis in these animals 
(2).  These studies and others implicate OPN in angiogenesis outside the context of 
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tumorigenesis, but no studies to date have fully elucidated the in vivo role of this factor in 
regulating postnatal blood vessel growth.  
OPN in Bone  
OPN, a multifunctional protein, is one of the major non-collagenous proteins in 
bone extracellular matrix, and it has been most extensively studied for its role in control 
of mineralization and remodeling in bone tissue.  In normal murine bone, OPN is 
expressed by osteoblasts, osteocytes, and hypertrophic chondrocytes (186).  OPN 
deficient mice have no obvious bone phenotype, and OPN was originally reported to play 
no major role in normal bone development (170,187).  However, in vitro studies have 
indicated that OPN binds tightly to hydroxyapatite, which leads to an inhibition of 
mineral crystal formation and growth (188,189).  Correspondingly, subsequent studies 
using Fourier transform infrared imaging found that OPN deficient mice possessed 
increased mineral content and crystallinity (190).  While OPN deficiency was originally 
found to result in grossly normal bones, initial reports found that osteoclast formation 
from OPN deficient cells was abnormal in vitro (187).  More recent studies have found 
that OPN-CD44 interaction is of great importance in bone tissue due to its role as an key 
mediator of osteoclast recruitment and function (187,191,192).  The in vivo importance of 
this interaction during bone remodeling has been further demonstrated by the fact that 
OPN deficient mice undergo significantly less bone resorption compared to wild type 
mice in response to reduction in mechanical loading, ovariectomy, stimulation by 
parathyroid hormone, or administration of a high phosphate diet (193-196).   
 In terms of bone fracture healing, in situ hybridization studies have noted OPN 
expression in the fracture callus by osteoprogenitors in woven bone, hypertrophic 
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chondrocytes in the transitional are between cartilage and bone, and in the osteocytes, 
osteoblasts, and osteoclasts of the hard callus (144,197,198).  In addition, OPN and CD44 
have been shown to be colocalized during late stage remodeling of the hard fracture 
callus, which indicates that the interaction of these molecules may also play a role in 
bone remodeling during fracture healing (197).  Based on these observational data gained 
from studying the temporal and spatial expression of OPN, scientists have speculated that 
OPN plays an important role in triggering mineralization during fracture healing (199).  
However, based on studies in tumorigenic and cardiovascular tissues, whether OPN 
initiates or inhibits ectopic calcification remains unclear (200,201).  In addition, although 
OPN is considered a primary marker of osteoblast differentiation, a recent report suggests 
that OPN is a negative regulator of proliferation and differentiation of osteoblasts and 
found that overexpression of OPN inhibited mineral deposition (202).  Furthermore, OPN 
is thought to be vital for osteoclast function and bone remodeling (191,192).  Considering 
this diversity of sometimes conflicting data, the overall effect of OPN on fracture healing 
remains to be understood.  Therefore, this thesis project has sought to more clearly 
elucidate the role of OPN in fracture healing in vivo.  
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CHAPTER 3 
QUANTITATIVE MICROCOMPUTED TOMOGRAPHY  
ANALYSIS OF COLLATERAL VESSEL DEVELOPMENT 
FOLLOWING ISCHEMIC INJURY  
Introduction 
Collateral vessel formation can functionally compensate for obstructive vascular 
lesions in patients with atherosclerosis.  Animal models of peripheral limb ischemia play 
a vital role in preclinical research efforts that test the efficacy of administering 
angiogenic factors and other therapeutic agents to stimulate formation of collaterals to 
compensate for blocked arteries.  One such model, the mouse hind limb ischemia model, 
has been used extensively in efforts to define the mechanisms involved in postnatal blood 
vessel formation (107).  While the utility of this model is well established, the available 
methodologies for quantification of collateral vessel development in this setting are not 
ideal.   
In the context of hind limb ischemia, three different mechanisms may contribute 
to reconstitution of limb perfusion.  Angiogenesis involves sprouting or intussusception 
of new capillaries from pre-existing vessels and is triggered by tissue ischemia.  
Arteriogenesis occurs when preexisting arterioles dilate and remodel through endothelial 
and smooth muscle cell expansion to meet increased physiologic demands (5,6).  It is 
generally accepted that this process, which is mediated at least in part by monocytes and 
macrophages, is triggered by the increased shear stress that occurs in small, interarterial 
anastomoses following occlusion of a parent artery (7).  Finally, there is evidence that 
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vasculogenesis or de novo blood vessel formation by bone-marrow derived endothelial 
progenitor cells may play a role in post-natal vessel growth, although this remains 
controversial (9).  Collateral vessel growth, primarily via an arteriogenic pathway, is 
widely believed to be the most efficient means for reconstituting perfusion following 
arterial occlusion (5).  
Investigators have utilized a variety of techniques to evaluate vascular structures 
in animal models.  Histology is commonly employed to analyze capillary or arteriole 
density, but it is relatively subjective, not truly quantitative, 2-D, and not necessarily 
representative of vascularity throughout the entire sample.  Laser Doppler perfusion 
imaging has been used to analyze functional blood flow in hind limbs because it offers 
semi-quantitative data and a measure of functionality (5,107,111-113).  However, this 
technique does not provide anatomical information and is limited by the fact that only the 
most superficial, cutaneous blood flow is measured.  Another popular technique, x-ray 
microangiography, provides high-resolution, 2-D angiograms of the hind limb vascular 
anatomy but lacks the ability to employ a quantitative, volumetric analysis (113-115).  
Injection of colored or fluorescent microspheres presents a method for longitudinal study 
of reconstitution of perfusion to ischemic tissues using quantitative spectrophotometry or 
flow cytometry analyses (116-120).  However, the required arterial catheterization or 
injection of microspheres into the left ventricle or atrium presents a considerable 
challenge in mice because of their small size.  Other imaging modalities such as magnetic 
resonance angiography and positron emission tomography serve as viable methods for 
analyzing vascular function, but the resolution of these methods is typically not sufficient 
for studies involving small animals.    
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Micro-CT has emerged as a promising technology that can overcome several of 
the challenges associated with evaluation of vascular networks.  Recently, vascular 
imaging procedures have been developed for small animal models based on the use of 
perfused contrast agents and x-ray micro-CT (121-129).  The goal of these studies has 
been to visualize 3-D vascular networks in organs (i.e. heart and kidneys) or tumors.  The 
objective of the current study was to use micro-CT vascular imaging methods to examine 
the time course of collateral formation induced by femoral artery excision in the mouse 
hind limb ischemia model.  In addition to vessel volume, measures of vascular network 
morphology and anisotropy were quantified and the effects of varying the imaging 
parameters voxel size and binarization threshold were analyzed.  The developed micro-
CT-based techniques represent an innovative and quantitative approach for investigating 
3-D vascular responses associated with a broad range of conditions, including vascular 
injury, tumorigenesis, coronary artery disease, aneurysm formation, skeletal 
development, and fracture healing.  In these settings, micro-CT imaging in combination 
with an appropriate contrast agent has the potential to overcome the shortcomings of 
other vascular imaging techniques because it can provide high resolution, volumetric, 
objective, and highly quantitative analyses. 
Methods 
Animals 
Male C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME).  All mice were between 10 and 11 weeks of age.  The animals were fed a standard 
chow diet ad libitum and had free access to water.  All protocols were approved by the 
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Institutional Animal Care and Use Committee of Emory University and done in 
accordance with the NIH guidelines for the care and use of experimental animals.      
Hind Limb Ischemia Model  
To study collateral formation, we utilized the well characterized mouse hind limb 
ischemia model (107).  Animals were anesthetized by intraperitoneal injection of 
xylazine (10 mg/kg) and ketamine (80 mg/kg).  All hair was removed from the surgical 
site and the area was thoroughly cleansed with sterile water.  A unilateral incision was 
then made over the right medial thigh of the mouse.  The superficial femoral artery and 
vein were ligated proximal to the caudally branching deep femoral artery, and then a 
second ligation was performed just proximal to the branching of the tibial arteries.  The 
length of the artery and vein was excised between the two ligation points, and the skin 
was closed with interrupted silk sutures.  After awakening, animals were returned to their 
cages and allowed to ambulate freely.  The mice were euthanized post-operatively for 
microcomputed tomography imaging at 0 (n=7), 3 (n=6), and 14 (n=5) days or 
histological analysis at 14 days (n=3).  
Imaging Specimen Preparation 
Tissues were prepared in concordance with previously described methods (121).  
Following euthanization, the thoracic cavity was opened and the inferior vena cava was 
severed.  The vasculature was flushed with 0.9% normal saline containing heparin 
sodium (100 units/mL) at a pressure of approximately 100 mm Hg via a needle inserted 
into the left ventricle.  Specimens were then pressure fixed with 10% neutral buffered 
formalin.  Formalin was flushed from the vessels using heparinized saline, and the 
vasculature was injected with either a 15% barium sulfate, 2% gelatin suspension or a 
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radiopaque silicone rubber compound containing lead chromate (Microfil MV-122, Flow 
Tech Inc., Carver, MA).   
In preliminary studies using barium-gelatin mixtures as the contrast agent, 15% 
barium sulfate and 2% gelatin were suspended into saline.  To prepare the contrast agent 
for perfusion, the gelatin was added a small amount at a time as the saline was heated on 
a stir plate.  The barium was subsequently added to the solution and the suspension was 
stirred until any clumps had dispersed.  The warmed solution was then perfused into the 
animal, which was subsequently placed on ice for one hour to promote gelling of the 
suspension within the vasculature.  Samples were then stored at 4 °C in 10% neutral 
buffered formalin until imaging.    
For studies using the silicone rubber injection agent, the manufacturer’s protocol 
was followed with the exception that no diluent was used in order to maximize the lead 
chromate content.  Samples were stored at 4°C overnight for contrast agent 
polymerization.  Mouse hind limbs were dissected from the specimens and soaked for 4 
days in 10% neutral buffered formalin to ensure complete tissue fixation.  Tissues were 
subsequently treated for 48 hours in a formic acid based solution, Cal Ex II (Fisher 
Scientific, Pittsburgh, PA), to decalcify the bone and facilitate image thresholding of the 
hind limb vasculature from the surrounding tissues.  Samples were rinsed thoroughly, 
soaked for 1 hour in water, and then stored at 4 °C in 10% neutral buffered formalin until 
microcomputed tomography imaging. 
Micro-CT Imaging 
Hind limb vasculature was imaged using a high-resolution (8-36 µm isotropic 
voxel size) desktop micro-CT imaging system (µCT 40, Scanco Medical, Bassersdorf, 
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Switzerland).  The scanner was set to a voltage of 55 kVp and a current of 145 µA.  
Resolution was set to medium, which created a 1024 x 1024 pixel image matrix.  Serial 
tomograms were reconstructed from raw data using a cone beam filtered backprojection 
algorithm adapted from Feldkamp et al (134).  Noise was removed using a low pass 
Gaussian filter (sigma=1.2, support=2).  The tomograms were globally thresholded based 
on x-ray attenuation and used to render binarized 3-D images of the hind limb vascular 
network segmented (i.e. partitioned) from the surrounding tissues.  Histomorphometric 
analysis based on direct distance transform methods was subsequently applied to the 3-D 
images to quantify parameters of vascular network morphology and anisotropy (135,136). 
Micro-CT Parametric Analysis 
One representative control (left) hind limb was chosen at random to test the 
effects of resolution and threshold on the histomorphometric analysis of vessel volume, 
connectivity, number, thickness, separation, and degree of anisotropy.  This specimen 
was scanned at voxel sizes of 16, 20, 30, and 36 µm.  The 36 µm voxel scan was used to 
test the effects of threshold on histomorphometric parameters.  A threshold of 80 was 
initially chosen based on visual interpretation of thresholded two-dimensional 
tomograms.  The 36 µm voxel size scan was evaluated to determine the output of the 
histomorphometric analysis using thresholds of 60, 70, 80, 90, and 100.  These threshold 
values directly correlate to the linear coefficient of attenuation of the material in the 




Analysis of Blood Vessel Morphology in Ischemic Hind Limbs 
Surgery and control limbs were evaluated individually to quantify the 3-D 
histomorphometric values vessel volume, connectivity, number, thickness, thickness 
distribution, separation, and degree of anisotropy (Table 3.1).  These parameters are 
standard for the analysis of trabecular bone microstructure but have not been determined 
previously for microvascular networks (136).  In this study, these measures were taken in 
a volume of interest (VOI) defined as the upper hind limb, extending from the proximal 
femoral artery ligation point distally to the lower ligation point.   
 
Table 3.1.  Overview of Vessel Morphology Parameters 
Parameter Unit Definition
Volume mm3 -Image voxel size multiplied by the number of voxels in segmented image
Connectivity 1/mm3 -Maximal number of branches that can be broken within a blood vessel 
network before it is divided into two unconnected parts
Number 1/mm -Inverse of the mean spacing between the mid-axes of the blood vessels
Thickness mm -Average of the local vessel thicknesses determined at each voxel 
within the segmented vessel network
Separation mm -Average of the distance between neighboring vessels determined at each 
voxel within the image background space
Degree of Anisotropy 1 -Determined based on the directional orientation of the vascular network 
(1 = isotropic; >1 = preferential orientation exists) 
 
Vessel volume was computed based on the voxel size and the number of 
segmented voxels in the 3-D image following application of the binarization threshold.  
Connectivity was determined using the method of Odgaard and Gunderson (137), which 
is based on the Euler characteristic and is free from assumptions on the three-dimensional 
structure of the segmented object.  Here, connectivity is defined as the maximal number 
of branches that can be broken within a structure before it is divided into two separate 
parts.  Vessel number, thickness, thickness distribution, and separation were calculated 
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using a model-independent method for assessing thickness in 3-D images (135).  This 
technique defines a local thickness at every point (voxel) in the VOI as the diameter of 
the largest sphere that both contains the point (not necessarily at its center) and is 
completely within the structure of interest (segmented object versus background space 
surrounding the object).  The average of the local voxel thicknesses within the structure 
yields the vessel thickness parameter, and a similar calculation on the background voxels 
determines the vessel separation.  To calculate vessel number, the segmented volume is 
skeletonized, leaving just the voxels at the mid axes of vessels in the structure.  Vessel 
number is defined as the inverse of the mean spacing between the mid-axes of the 
structures in the segmented volume.  Degree of anisotropy represents the degree to which 
the segmented vascular bed is oriented toward a specific direction.  It is measured by 
determining the mean intercept length of blood vessels as a function of direction.  
Eigenanalysis is used to find the principal material directions, and, after this is 
determined, the ratio of the maximum and minimum eigenvalues yields the degree of 
anisotropy as described by Gunderson et al (203).  A degree of anisotropy of 1.0 indicates 
that the network is perfectly isotropic, or does not contain a preferred orientation, and 
higher values of degree of anisotropy indicate that a structure contains a preferential 
material direction. 
  Using the semi-automated software that interfaces with the µCT 40 scanner, 
histograms were generated to display the distribution of the vessel sizes within the 
volume of interest.  Volume weighted histograms were created that display the local 
thickness value for every point within the structure.  In addition, a color-coded scale was 
mapped to the surface of the 3-D images to produce a visual representation of the vessel 
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size distribution.  These images contain a color-coded map that correlates to vessel 
diameter. 
Histological Analysis 
Mice were euthanized, cleared using heparinized 0.9% normal saline, and 
perfusion fixed using 10% neutral buffered formalin.  The adductor muscles were then 
excised from both the occluded and control limbs of each mouse.  These tissues were 
processed and paraffin embedded for histological analysis.  5 µm thick sections were cut 
and immunostained with a mouse monoclonal smooth muscle α-actin antibody (Sigma 
Chemical, St. Louis, MO).  In order to count arterioles using light microscopy, the 
primary antibody was detected using an avidin-biotin-alkaline phosphatase method from 
a commercially available kit (Vectastain ABC-AP, Vector Laboratories, Burlingame, 
CA).  Sections were counterstained with hematoxylin, and the number of positively 
stained vessels was counted from two transverse tissue sections taken 150 microns apart 
at approximately 5 mm from the proximal insertion of the adductor.  Arteriole densities 
were counted as the number of vessels per square millimeter and reported as ratio 
between the surgery and control limb for each specimen. 
To qualitatively assess the ability of micro-CT to resolve vascular structures using 
different image resolutions, approximately 1 mm thick transverse cross sections of tissue 
were cut from the upper hind limb of contrast perfused specimens.  These samples were 
then sequentially treated in 25%, 50%, 75%, 95%, and absolute ethanol for 24 hours 
each, followed by 24 hours in methyl salicylate (Sigma Chemical, St. Louis, MO) for 
tissue clearing.  The cleared tissues were first transilluminated and photographed using a 
high-resolution digital camera.  These same sections were then scanned using 8, 16, and 
 48
36 µm voxel sizes in order to qualitatively evaluate micro-CT in rendering the localized 
vascular structures. 
Statistical Analysis  
All data are presented as mean ± SEM.  Statistical analyses were performed using 
the Minitab software.  Tukey’s method was used for post hoc analyses, and ANOVA was 
used to model the effect of time post surgery on all response variables.  P<0.05 was 
interpreted as significant in all analyses.     
Results 
Evolution of Micro-CT Imaging and Hind Limb Ischemia Model Surgery 
Techniques 
In preliminary studies, perfusion of barium sulfate and gelatin suspensions was 
used to enhance x-ray attenuation of the vasculature.  Using this method, high resolution 
images of the hind limb vascular networks could only be generated at low thresholds that 
did not remove bone from the image.  In order to eliminate the confounding effects bone 
imaging would have on the morphological analyses, we attempted to use higher 
thresholds to segment the vasculature only.  However, this significantly diminished 
image quality (Figure 3.1).  Conversely, closer inspection showed that, due to the high 
radiodensity of barium sulfate, the segmented object often appeared artifactually large 
when lower threshold values were used.  Further investigation also demonstrated that the 
barium sulfate settled within the vessels after removing it from 4°C to place it within the 
micro-CT scanner, resulting in incomplete vascular filling and an inhomogeneous 
coefficient of attenuation within the vessels. 
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After gaining insight into some of the disadvantages of using barium sulfate in a 
gel suspension, we began to employ a silicone rubber contrast agent, which provides x-
ray attenuation due to its lead chromate content.  This compound polymerizes into a 
silicone rubber solid approximately 20 minutes after it is catalyzed by addition of a 
curing agent.  Compared to preliminary studies using barium sulfate, the polymerized 
compound lowered the risk of displacing the contrast when manipulating the tissues to 
prepare for imaging.  This compound also allowed us to maintain a more homogeneous 
mixture and hence x-ray attenuation within the vessels independent of the environment 
within the scanner during imaging.   
Although the contrast agent formulation was chosen to maximize contrast of the 
perfused vasculature, image segmentation of vascular structures from bone remained a 
challenge.  To circumvent this problem, specimens were placed in a decalcification 
solution for 48 hours.  Following this treatment, a lower threshold could be used to 
segment the vasculature from the surrounding tissues, and superior quality images were 
produced (Figure 3.1 C and D).  Improved imaging techniques also led to optimization of 
the surgery protocol.  Figure 3.1 C illustrates that in pilot studies, the upper ligation point 
was too distal to prevent perfusion of major arteries branching from the femoral artery 
that supply the lower limb.  Following this observation, shifting the ligation point 
proximally to preclude the branching of the deep femoral artery allowed us to create a 







Figure 3.1.  Micro-CT angiograms demonstrating the progression of our hind limb 
ischemia model specimen preparation and surgical techniques. (A) and (B) show images 
from preliminary studies using a 15% barium, 2% gelatin suspension as a contrast agent 
for vascular imaging.  To remove the bone tissue from the image (B), use of a high 
threshold results in loss of small blood vessel definition that is evident at a lower 
threshold (A).  Images in (C) and (D) were acquired following vascular perfusion using a 
silicon polymer and bone decalcification, which allows use of a lower threshold.  These 
techniques circumvented previous problems associated with settling of barium particles 
within the suspension and thresholding out bone.  Image (C), a day 0 post surgery 
control, showed that our original surgical procedures ligated the femoral artery too 
distally to preclude blood flow in arteries that can supply blood to the lower leg.  Image 
(D), another day 0 post surgery control, demonstrates optimization of the surgical 
protocol by shifting the proximal ligation point.  The dashed boxes represent the volume 
of interest considered in the control and surgery limbs for all morphological analyses.     
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Effects of Voxel Size and Binarization Threshold on Quantification of Vascular 
Network Morphological Parameters  
Isotropic voxel size is a main determinant of the ability to resolve small objects on 
micro-CT scans and thus affects image quality.  While smaller voxel sizes result in longer 
scan times and much larger data sets, it can be seen in Figure 3.2 A that they also afford 
the opportunity to resolve smaller caliber vessels that can’t be visualized with larger 
voxel sizes.  When evaluating the VOI defined in Figure 3.1 D for a representative 
control limb, it was evident that voxel resolution affects the different morphological 
parameters to varied degrees (Figure 3.2 B).  Vascular volume decreased as voxel size 
increased due to the contribution of smaller vessels that could only be resolved when 
smaller voxel sizes were used.  Vessel connectivity, the most drastically affected 
parameter, decreased markedly on larger voxel size scans that did not resolve the well-
connected networks of small arterioles.  In agreement with this conclusion, there was a 
discernable decrease in vessel number and an evident increase in both average vessel 
thickness and vessel separation at larger voxel sizes.  Degree of anisotropy, one of the 
more mildly effected parameters, increased with larger voxel sizes, indicating that the 
smaller vessel networks resolved at smaller voxel sizes were more randomly oriented 
than the primary arteries.       
Selection of an image threshold defines the cutoff grayscale (attenuation) value 
that partitions the image voxels into either the background or part of the segmented 
object.  During reconstruction of image projections, a grayscale value that represents the 
capacity of the material within that space to attenuate x-rays is assigned to each voxel.  If 
this coefficient is higher than the assigned threshold, the voxel remains in the 3-D image 
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as part of the segmented object.  Selection of an optimal threshold value is made 
especially challenging by attempting to account for partial volume effects.  At lower 
thresholds, smaller vessels that are apparent on the 2-D tomograms will remain as part of 
the segmented object, but larger vessels will appear artifactually large because the 
partially filled voxels surrounding them will remain in the image.  Conversely, to gain the 
most accurate image of the larger vessels, a higher threshold must be used, and smaller 
vessels are often omitted from the 3-D rendering (Figure 3.3 A).  Therefore, there is a 
tradeoff that exists, and when global thresholding is used, careful attention must be paid 
in choosing the best possible threshold. 
The ability to define an appropriate threshold for binarizing computed 
tomography data sets is an important issue to resolve before completing a morphological 
analysis of the rendered 3-D image.   Alteration of the threshold value had an observable 
effect on the morphometric parameters of the vascular tree, but this effect was not as 
substantial as that seen from varying voxel size (Figure 3.3 B).  Vascular volume, 
connectivity, and vessel number all decreased with increasing threshold with, as before in 
the resolution test, connectivity being the most strongly affected parameter.  Increasing 
the threshold also resulted in higher average thickness, separation, and degree of 
anisotropy of the vessel network.  As with increasing voxel size, these trends result from 
removing smaller, partial voxel vessels from the segmented volume. 
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Figure 3.2.  Voxel size sensitivity analysis.  (A) Representative control limb micro-CT 
angiograms illustrating the effects of scanning the same sample at different resolutions.  
Image voxel size is listed in the lower left of each image.  (B) Demonstration of the 
differences in the quantitative, morphometric parameters when 16, 20, 30, or 36 µm 
isotropic voxel sizes are used.  All parameters are affected by altering voxel size.  As 
voxel size is increased, vascular volume, connectivity, and vessel number decrease while 
average vessel thickness, average vessel separation, and degree of anisotropy increase.  
These trends result from the fact that the smallest vessels are not resolved at larger voxel 
sizes.   
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Figure 3.3. Threshold sensitivity analysis. (A) Representative control limb angiograms 
indicating the effects of using different binarization thresholds to produce rendered 3-D 
images from the same raw data set.  (B) Demonstration of the changes in the 
morphological parameters based on using 60, 70, 80, 90, and 100 as the binarization 
threshold to evaluate the 36 µm resolution scan.  All morphologic parameters are 
affected to some degree by varying the threshold, with connectivity showing the most 
drastic changes.  As threshold is increased, partial volume voxels are removed from the 
image.  This results in a decrease in vascular volume, connectivity, and vessel number 
with a concurrent increase in vessel thickness, separation, and degree of anisotropy.        
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Comparison of Control and Surgically Manipulated Hind Limb Blood Vessel 
Morphology 
In order to obtain a more quantitative assessment of the forming collateral 
network, we evaluated the potential utility of several morphological parameters.  As 
described in the methods section, vessel volume, connectivity, number, thickness, 
separation, and degree of anisotropy were determined for both the control and surgically 
manipulated limbs of all experimental animals (Figure 3.4).  In acute preparations (day 0 
post surgery), vascular volume was significantly reduced in experimental limbs compared 
to control limbs immediately following femoral artery excision.  However, as early as 3 
days post surgery, collateral vessels formed and the reconstituted vascular volume of the 
surgery legs was significantly higher than day 0 preparations.  In fact, at both 3 and 14 
days post surgery, the vascular volume was completely recovered and was not different 
from control limbs.  Connectivity of the vascular network in the surgery limbs was 
significantly less than in controls at day 0, but it increased rapidly post surgery.  While 
there was a trend toward increased connectivity at day 3, at 14 days, a more developed 
collateral system was formed, resulting in a connectivity value that was significantly 
higher than both 0-day surgery limbs and the contralateral control limbs.  As the 
collateral network grew and a series of small, densely packed vessels augmented blood 
flow to the hind limb, the 3 and 14-day post surgery hind limbs had significantly 
increased vessel number compared to day 0 surgery limbs or control limbs.  Average 
vessel thickness was decreased significantly following surgery and remained significantly 
lower at 3 and 14 days than in the intact control limbs, which contained the large, conduit 
femoral artery.  There was a non-significant trend toward increased vessel separation in 
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acutely prepared samples, but as the collateral network developed, at 3 and 14 days post 
surgery, vessel separation became significantly less than in control or day 0 specimens.  
Lastly, surgery limb degree of anisotropy was significantly reduced compared to controls 
at all time points, indicating that the new collateral network was more isotropic than the 
original intact vessel network.  These data indicate that vascular volume, vessel network 
connectivity, vessel number, and vessel separation may be particularly useful parameters 
for quantifying adaptive vascular changes following surgery in the hind limb ischemia 
model. 
As an additional method of analysis, histograms were compiled to show the blood 
vessel size frequency distribution in the control and experimental limbs 0, 3, and 14 days 
post surgery (Figure 3.5).  Control limbs represent the normal anatomical distribution of 
blood vessel sizes in non-manipulated limbs.  Immediately post surgery (day 0), the 
ischemic limb had reduced perfusion to all vessel sizes.  Relative to control limbs, 3-day 
and 14-day post surgery legs showed an increase in small, collateral-sized vessels and a 
decrease in the larger, conduit vessel diameters (14-day data not shown).  In addition, a 
visual representation of the blood vessel size distribution was produced by mapping a 























































































































































































Figure 3.4.  Demonstration of serial changes in quantitative assessment of vascular 
morphology after femoral artery ligation.  Histomorphometric analysis of (A) vascular 
volume (B) connectivity (C) vessel number (D) vessel thickness (E) vessel separation 
and (F) vascular tree degree of anisotropy.  Results (mean ± SEM) are given for control 
limbs (n=18) and surgery limbs 0 (n=7), 3 (n=6), and 14 days (n=5) post surgery (PS).  
∗ = significant difference (P<0.04) compared with control limb at a given time point.  ‡ 
= significant difference (P<0.01) between the indicated time point and 0-day post 
surgery specimens.  † (P<0.02) denotes that the histomorphometric parameter changes 
significantly in surgically manipulated hind limbs as a function of time post surgery as 
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Figure 3.5.  Vessel diameter histogram.  This histogram shows mean blood vessel size 
distribution in control limbs (n=13) and experimental limbs 0 (n=7) or 3 days (n=6) 
post surgery.  Control limbs represent the normal anatomical distribution of blood 
vessel sizes in non-manipulated limbs.  0 days post surgery, the ischemic limb has 
reduced perfusion to all vessel sizes.  Relative to control limbs, 3-day post surgery legs 
showed an increase in small, collateral-sized vessels and a decrease in the larger, 
conduit vessel diameters.  Since the trends were the same as those seen at 3 days, 14-
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Figure 3.6.  Representative 14-day post surgery micro-CT images with a color-coded 
vessel diameter scale mapped to the 3-D image surface.  (A) Rendering of an entire 
hind limb. (B) shows the volume of interest analyzed in the surgically modified and 
control limbs.  In these images, the color scale correlates to vessel size.  Red is mapped 
to the surface of vessels with diameter greater than or equal to 396 µm, and the color 
scale is linear down to zero.  Length scale bars are shown in the lower right of each 
image. 
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Comparison of Micro-CT and Histological Analysis       
In order to confirm our micro-CT data using a previously used technique, we 
performed arteriole density analyses after smooth muscle α-actin staining.  Since it is 
difficult to directly validate the micro-CT calculations, we compared the ratio of the 
surgery and control limb vessel number as determined by micro-CT with a similar ratio 
for the histologically determined arteriole density values.  There was excellent agreement 
between these two methods at 14 days post surgery, at which point the ratio of vessel 
number in the surgical and control limbs was determined to be 1.26±0.07 using micro-CT 
and 1.28±0.28 using histology (Figure 3.7 A). 
 To further evaluate the accuracy of micro-CT in depicting localized vascular 
structures, a small, 1 mm section of tissue from a contrast filled hind limb was cleared 
and photographed yielding a vivid and precise representation of the vasculature.  A 
qualitative comparison of this photograph and 8, 16, and 36 µm voxel size micro-CT 
images of the same specimen illustrates that micro-CT has the capability to accurately 
depict the smallest vessels when high resolution scans are used, but only larger arterioles 










































































Figure 3.7.  Histological Validation.  (A) Example photomicrographs of muscle cross 
sections from 14-day post surgery control and experimental limb adductors identifying 
arterioles using a smooth muscle α-actin antibody and counterstained with hematoxylin.  
Quantification shows excellent agreement between the histological and micro-CT 
determinations of the surgery to control limb vessel number ratio.  (B) Qualitative 
assessment of micro-CT vascular imaging using different voxel sizes.  A representative 1 
mm thick transverse tissue section was taken from a contrast-filled hind limb in the region 
shown.  This tissue specimen was cleared using methyl salicylate and imaged with high 
resolution digital photography and micro-CT at voxel sizes of 8, 16, and 36 µm.  These 
images illustrate that, as micro-CT voxel size is increased, small vessels are no longer 
clearly depicted while large arterioles and arteries are still accurately resolved. 
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Discussion 
Small animal models have been utilized to study the mechanisms of angiogenesis 
and collateral vessel growth (99,100,107,204).  Insights gained from these models have 
played a role in the design of therapeutic strategies for clinical trials aimed at recovering 
vascular function in patients with peripheral artery disease (34,205-212).  Despite 
advances in analysis of these models, no current method offers an optimal analysis of 
blood vessel microarchitecture and function.  The current study demonstrates that micro-
CT imaging combined with the use of perfused contrast agents and bone decalcification 
provides a robust methodology for evaluation of vascular networks.  Specifically, micro-
CT is advantageous because it provides high resolution, quantitative, 3-D, and objective 
data analysis.  This was evident in our validation study using immunohistochemistry, 
which found micro-CT to offer a highly accurate, less variable, and less time consuming 
alternative for quantitative measure of collateral development.  Micro-CT techniques also 
offer flexibility to the user in defining the volume of interest be evaluated.  A global 
analysis of the entire surgery and contralateral control hind limb vascular anatomy can be 
evaluated for comparative purposes, or if desired, the collateral vessels that form in the 
thigh can be digitally isolated for morphological evaluation as was done in this study.  
Alternatively, the functional reconstitution of the vascular network can be assayed by 
defining the VOI as the distal portion of the hind limb in order to quantify perfusion to 
the large conduit vessels in the lower portion of the leg.  Thus, contrast-enhanced micro-
CT imaging provides broad applicability to model systems that require a vigorous and 
highly quantitative evaluation of vascular structure or growth. 
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We examined vascular anatomy in the thigh of surgically manipulated and control 
hind limbs of wild type mice 0, 3, and 14 days following femoral artery ligation and 
excision.  The blood vessel networks were evaluated within this VOI for vessel volume, 
connectivity, number, thickness, thickness distribution, separation, and degree of 
anisotropy.  These lumped assessments of the vascular morphology led to the conclusion 
that removal of the large, conduit femoral artery stimulates reconstitution of vascular 
volume through a highly connected network of closely spaced, small vessels.  
Alternatively, histograms displaying a parameter’s distribution within the specimen can 
be advantageous for alternative indices such as average vessel thickness.  When the 
distribution of vessel diameters is evaluated, more information can be gathered and 
otherwise undetectable trends may become apparent.  For example, at 0, 3, and 14 days 
post surgery, no significant difference in average vessel thickness was apparent, but clear 
differences were seen when the thickness distribution was calculated (Figure 3.5). 
The rapid arteriogenic response detected represents a particularly interesting 
observation.  Previous researchers have suggested that arteriogenesis is temporally 
dissociated from angiogenesis, and it has also been suggested that arterialization of 
preexisting vessels, rather than sprouting of new capillaries, is a more efficient means of 
establishing collateral flow following femoral artery ligation (5,7,213,214).  Our data 
demonstrate that vascular volume of angiographically visible vessels was completely 
reconstituted compared to control as early as 3 days following surgery.  Furthermore, 
there was no significant difference between 3 and 14-day post surgery specimens for any 
of the morphological parameters evaluated.  Multiple researchers have reported different 
capacities for angiogenesis and collateral development in different background strains of 
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mice (5,215,216).  The rapid response to occlusion observed here corroborates the work 
by Scholz et al indicating that, unlike other strains, resting hind limb perfusion in the 
inbred C57BL/6 mouse strain is significantly recovered as early as 3 days post surgery 
(5).  Here, the authors found that the process of collateralization is so fast and efficient in 
these mice that ischemia is minimized and angiogenesis, therefore, does not occur.  
The tradeoffs that exist when defining the binarization threshold and the scanning 
resolution are important methodological cautions that must be considered when using 
micro-CT imaging for analysis of vascular structures.  When defining the binarization 
threshold, a value that is too high will delete small vessels from the image, but a 
threshold that is too low can make major vessels appear artifactually large.  It is our 
recommendation that the user makes a visual determination of the optimal threshold by 
assessing several specimens and then keeps this value constant for all evaluations within 
a study.  This value should be chosen based on the threshold that allows the capture of the 
intricate details with minimal overestimation of broader structures.   
We believe that choosing the voxel size of the scan should be chosen based on the 
proposed application.  Scanning with smaller voxel sizes provides more information by 
resolving smaller vessels that cannot be detected at larger voxel sizes.  However, based 
on the type of information sought and sample throughput considerations, scanning at a 
larger voxel resolutions can be more effective for some applications.  For example, when 
using the mouse hind limb ischemia model, we were interested in gaining a global 
perspective of collateral growth in the upper thigh as is commonly done in 2-D by 
investigators who utilize x-ray microangiography.  We believe that a voxel size of 36 µm 
is the best choice for this application because it allows us to preferentially focus our 
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analysis on the larger, arteriole-sized vessels, which are the best indicators of ischemic 
limb recovery.  However, as shown here through voxel size sensitivity analysis and 
assessment of different micro-CT voxel sizes for resolving local vascular anatomy in 
cleared tissue sections, higher resolution scans are necessary to image smaller vascular 
structures.   For example, a voxel size of 8 µm or smaller may be required for studies 
whose aim is to measure angiogenesis or small blood vessel structure within a confined 
area (i.e. tumor growth or fracture healing models).   When using smaller voxel sizes, the 
major disadvantage is the increased scan time, along with the increased computational 
time and complexity required for analyses of a much larger data set.   
Another possible drawback of the techniques used in this study is that they do not 
allow for longitudinal analyses at different time points within the same animal.  Since this 
is a post-mortem analysis, the number of animals required for completion of a time 
course study is increased compared to methods such as laser Doppler perfusion imaging, 
which offers the ability to acquire multiple scans on the same living animal at different 
time points post surgery.  The recent commercial availability of high speed in vivo micro-
CT scanners that provide maintenance of animal anesthesia within the scanning system 
may remedy this limitation.  However, before using these systems, one must consider the 
possible adverse biological effects that may result from repeated exposure of the animals 
to anesthetics and relatively high doses of x-ray radiation that would occur in a sequential 
study.  In addition, the increased image quality afforded by decalcifying specimens will 
not be feasible in the in vivo systems.  Other potential challenges presented by this 
technology are development of non-toxic contrast agents that persist in the bloodstream 
 66
long enough for image acquisition and gating methods to account for heartbeat and 
respiratory movements during the scan.  
Previous studies that involved micro-CT imaging of the vasculature 
predominantly have used either barium sulfate based contrast agents (129,217,218) or 
polymerizing compounds containing lead chromate (121-127).  As shown in our 
preliminary studies, choice of the ideal contrast agent can be a strong determinant of 
image quality for some applications.  We found the polymerizing agent to be far superior 
for the hind limb ischemia model, but it is our recommendation that both contrast agents 
can potentially be useful depending upon the application.  In this study, the silicon 
polymer was shown to be ideal for imaging collateral development compared to barium 
sulfate because it allowed us to circumvent problems such as settling and lack of 
homogeneity within the vasculature, clumping during injection, and difficulty with 
perfusion due to high viscosity.  However, the presence of bone, a similarly attenuating 
material, required decalcification when global thresholding was used to segment the 
vasculature from surrounding tissues.  The ability to mix barium sulfate to higher 
concentrations allows the possibility to achieve a stronger attenuating contrast agent and, 
therefore, allows use of a higher binarization threshold.  As a result, barium sulfate can 
provide sufficient image thresholding of large arterial vessels even without bone 
decalcification, but high viscosity may limit the ability to perfuse small arterioles and the 
venous circulation.   
Micro-CT has several superior features compared to other techniques for blood 
vessel morphological evaluation, but ultimately, the ideal strategy for microvascular 
analysis may include multiple methods that allow for both anatomical and functional 
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measures.  The micro-CT vascular imaging methodology has the flexibility and potential 
to be adapted to other applications where vascular structures must be analyzed in a 
rigorous and quantitative fashion (e.g., fracture healing, tumor angiogenesis, coronary 
collateral growth, etc.).  The most significant limitation of micro-CT is that it is a strictly 
anatomical assessment.  While inferences regarding physiologic function can be deduced 
from micro-CT images, its strength is in the quantitative anatomical information it 
provides.  Therefore, combining micro-CT with a more powerful method for functional 
analysis such as laser Doppler perfusion imaging, MRA, or micro-PET may provide the 
most comprehensive evaluation of vascular network structure and function.  
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CHAPTER 4 
THE ROLE OF OSTEOPONTIN 
 IN POSTNATAL VASCULAR GROWTH 
Introduction 
Peripheral arterial occlusive disease (PAD) causes obstruction of flow in arteries, 
typically in the lower limbs, and is caused primarily by atherosclerosis.  These 
obstructions can cause intermittent or chronic ischemia and pain in the extremities, which 
can lead to amputation in the most severe cases.  PAD affects 17% of men and 21% of 
women who are 55 years or older, but prevalence is much higher in smokers and those 
with diabetes mellitus, with advanced disease progression being much more common in 
patients with these risk factors (219).  Therapeutic angiogenesis, stimulation of new 
blood vessel formation to increase blood flow to ischemic tissues, presents a relatively 
new clinical approach for alleviating the deleterious effects of PAD.    
 Although this strategy is termed “therapeutic angiogenesis”, the goal is to increase 
perfusion to ischemic tissues by any means possible, including arteriogenesis and 
vasculogenesis.  The majority of studies geared toward development of therapeutic 
angiogenesis treatments have focused on the clinical potential of growth factor delivery 
(i.e. VEGF or FGF) or stem cell therapy (i.e. EPCs).  Preclinical data using either VEGF 
or FGF have shown tremendous promise in a variety of animal models (26-30).  
Unfortunately, the initial human trials have not corroborated these results and have 
shown almost no improvement in clinical outcome (31-34).  Cell therapy has also shown 
accelerated recovery from ischemia in animal work (59-62).  By most accounts, clinical 
trials using cell therapy have been more favorable than those using growth factors, yet the 
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levels of clinical improvement have been modest (81,82).  While therapeutic 
angiogenesis trials have shown enough clinical potential to warrant further investigation, 
improved efficacy will be necessary before any of these techniques can gain broad 
clinical use.  To do so, it will be imperative that scientists are able to better define the 
roles of all factors involved in postnatal vascular growth, and clinicians must carefully 
consider the roles of other mediators, such as ECM proteins, in addition to the potential 
synergistic effects of using combined growth factor and cell therapies.   
 Previous studies have pinpointed several factors that, when studied in isolation, 
appear to play a significant role in the process of postnatal vascular growth.  However, 
restoration of ischemic limb perfusion requires a precise interplay between numerous cell 
types, growth factors, and cues provided by the extracellular environment.  In order to 
better develop therapeutic angiogenesis regimens, each of these areas must be better 
understood in isolation and more importantly, in the context of their interactions with 
each other.  The ECM, which is probably the most neglected of these three areas, 
provides the structural scaffolding that maintains the organization of vascular cells into 
blood vessels and initiates signals that stimulate events such as cellular survival, 
proliferation, and migration.  In order to better understand this aspect of collateral vessel 
formation, we have focused on the role of the ECM protein osteopontin during ischemic 
limb revascularization. 
OPN is synthesized as a 34-kDa protein and functions in a variety of biological 
processes including, but not limited to, inflammatory response, immunity, wound repair, 
tumor formation and metastasis, cell adhesion, cell migration, and bone mineralization 
and remodeling.  OPN has been classified by some as a “matricellular protein”, a 
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categorization for nonfibrillar, bioactive ECM proteins that are thought to mediate 
cellular functions by providing a functional link between cell surface receptors, structural 
ECM molecules, and cytokines, growth factors, and proteases (156).  OPN interacts with 
as many as seven different integrins through its RGD or more novel SVVYGLR binding 
sequences (155,157-161).  Many of these integrin interactions are regulated by thrombin 
cleavage, which is thought to increase accessibility of cell receptors to their binding 
domains and greatly enhance the cellular effects of OPN (162).  Also, an intracellular 
form of OPN that localizes to the cell membrane where it binds to the cell surface 
glycoprotein CD44 has been found to be an integral component in cell migration 
(165,167).   
Although OPN was originally isolated from bone, it has also been found to be 
important for normal arterial physiology (173).  Albeit in the context of atherogenesis, 
OPN has been found to be produced by the three primary cell types traditionally thought 
to participate in blood vessel growth: monocytes/macrophages, endothelial cells, and 
smooth muscle cells (174).  Previous in vitro studies have demonstrated that vascular cell 
interactions with OPN mediated through cell surface integrins regulate a variety of 
cellular functions that are potentially important to angiogenesis and arteriogenesis.  In 
this context, OPN signaling through the αvβ3 integrin has been found to mediate 
endothelial cell survival in a process that involves the NF-κB signaling pathway (175).  
Also, the angiogenic growth factor VEGF has been shown to trigger an increase in αvβ3 
expression, OPN expression, and thrombin cleavage of OPN, which provides a 
cooperative mechanism that enhances endothelial cell migration (176).  In addition, OPN 
expression is induced by stimulation with FGF, and this cross-talk may provide a 
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mechanism for recruitment of monocytes and amplification of FGF-induced angiogenesis 
(177).  OPN also mediates several processes relevant to arteriogenic collateral vessel 
formation including adhesion and migration of both macrophages and smooth muscle 
cells. (178-180).  There have been a small number of in vivo studies that have implicated 
OPN in postnatal neovascularization.  For example, OPN mRNA has been shown to be 
locally upregulated at sites of ischemia-induced retinal neovascularization in mice (3), 
and OPN has been found to correlate with progression of the angiogenesis-related 
processes tumorigenesis and metastasis (169).    
Based on the observations discussed above, it is likely that the vascular effects of 
OPN are also relevant in recovery from limb ischemia.  However, the specific function of 
OPN during ischemic limb revascularization has not been previously determined.  In the 
present study, we hypothesized that OPN deficiency reduces postnatal vascular growth 
and delays reperfusion of ischemic tissues and recovery of limb functionality.  To test 
this hypothesis, we have investigated in vivo hind limb ischemia and in vitro cellular 
function assays in wild type and OPN-/- mice.  For the in vivo model, endpoints included 
anatomical quantification of the collateral vasculature, measurement of physiological 
blood perfusion, and functional assessment of exercise endurance.  For in vitro studies, 
endpoints included endothelial cell sprouting and tube formation, in addition to 
evaluation of macrophage migration. 
Methods 
Mice 
Male wild type C57BL/6 mice were purchased from the Jackson Laboratory.  
Osteopontin deficient mice were originally received from Dr. Lucy Liaw of the Maine 
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Medical Center, and they were subsequently backcrossed ten generations onto the 
C57BL/6 background.  All animals were fed a standard chow and had free access to 
water.  All protocols were approved by the Institutional Animal Care and Use Committee 
and done in accordance with the federal guidelines on the principles for the care and use 
of animals in research.    
Hind Limb Ischemia Model 
Animals were anesthetized by intraperitoneal injection of xylazine (10 mg/kg) and 
ketamine (80 mg/kg).  All hair was removed from the surgical site, and the area was 
cleansed with sterile water followed by betadine.  A unilateral incision was then made 
over the right medial thigh of the mouse.  The superficial femoral artery and vein were 
ligated proximal to the caudally branching deep femoral artery, and a second ligation was 
performed just proximal to the branching of the tibial arteries.  The femoral nerve was 
left intact and dissected away from the vasculature between the proximal and distal 
ligation.  The length of the artery and vein was separated from surrounding tissues and 
excised between the two ligation points.   The skin was then closed with interrupted silk 
sutures.  The mice were allowed to recover on a heated pad, and, after awakening, they 
were returned to their cages and allowed to ambulate freely.   
Micro-CT Imaging of Collateral Vessels 
Novel quantitative micro-CT based methods developed in our laboratory were 
utilized for evaluation of ischemic limb collateralization (130).  Mice were sacrificed 
using carbon dioxide inhalation at 7 days post surgery (wild type n=7, OPN-/- n=7).  The 
vasculature of the mice was sequentially perfused at physiologic pressure using 
heparinized (100 units/mL) normal saline, 10% neutral buffered formalin, and then again 
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with heparinized saline.  The vascular system was subsequently injected with a 
radiopaque, lead chromate based contrast agent (Flow Tech Inc.), which was then 
allowed to polymerize for 24 hours at 4°C.  The mouse hind limbs were then dissected 
free from the remainder of the animal and placed in 10% neutral buffered formalin for 48 
hours.  Afterwards, the specimens were soaked for 48 hours in a formic acid based 
solution (Cal-Ex II, Fisher Scientific) for decalcification of the mineralized bone, washed 
thoroughly using water, and placed in 10% neutral buffered formalin until imaging.  The 
vasculature located between the proximal ligation point and the ankle was imaged at a 
30-µm voxel size, and the tomograms were globally thresholded based on x-ray 
attenuation and used to render binarized 3-D images of the hind limb vascular network 
segmented from the surrounding tissues.  These 3-D images were evaluated for vascular 
volume. 
Laser Doppler Perfusion Imaging 
Laser Doppler Perfusion Imaging was completed 3, 7, and 14 days post surgery to 
assess perfusion to the paw of the ischemic limb (n=11-14 for each genotype at each time 
point).  Mice were anesthetized with xylazine (10 mg/kg) and ketamine (80 mg/kg) and 
scanned with laser Doppler perfusion (PIM II Laser Doppler Perfusion Imager).  To do 
so, anesthetized animals were placed in the supine position on a heating pad under the 
laser scanner.  The lower limbs were imaged, and the footpad was chosen as the region of 
interest for calculation of perfusion values.  To account for possible differences in 
ambient temperature and lighting, the ratio was calculated for the average perfusion in the 
foot of the ischemic leg to the foot of the control leg. 
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Swim Endurance Test 
As a physiologic test of ischemic limb functional recovery, experiments 
measuring swim time until exhaustion were completed.  To do so, we built a current pool 
that stimulates forced swimming in mice (220).  This apparatus possesses a roller pump 
that can generate a surface current, forcing the mice to swim upstream as shown in the 
schematic in Figure 4.1.  The water temperature was maintained at 35°C with a 
submersible heater (Cole Parmer), and, using the pump, flow rates of 5 L/min were 
generated.  Prior to onset of hind limb ischemia, mice were trained for 5 minutes per day 
for 7 days in order to acclimate the animals to swimming.  At 5 days post-surgery, 
maximal exercise capacity was defined as the amount of time the animal could swim 
against the current before experiencing 5 consecutive seconds of submersion, at which 
point the mouse was removed from the tank (wild type n=8, OPN-/- n=8).  
  
 
Figure 4.1.  Schematic of flow tank for testing exercise endurance.  In this system, a 
current is generated on the surface of the water in the tank.  This surface current flows 
through a vent into the collection reservoir and recirculates to the flow reservoir.   
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Mouse Serum Isolation 
Mice were euthanized with carbon dioxide inhalation.  Blood was immediately 
taken from the right ventricle using a 21-gauge needle.  Blood samples were left to 
coagulate for 45 minutes at room temperature.  They were then centrifuged, and the 
serum supernatants were pipetted from the samples, sterilized using a syringe filter, and 
frozen at –80°C until use.   
Aortic Ring Vascular Sprouting Assay 
The mouse aortic ring assay was utilized as previously described (96).  1.5% 
agarose wells were created with an inner diameter of 10 mm and an outer diameter of 17 
mm.  Three of these wells were placed into each 60 mm bacterial culture dish.  The aorta 
was dissected from the mouse and placed into cold serum free DMEM containing 
penicillin and streptomycin.  The adventitial layer was carefully dissected away, and 1 
mm sections were cut from the mid-thoracic region of the aorta.  These rings were rinsed 
2-3 times in cold DMEM and then embedded in collagen gels.  In order to stain 
endothelial cells prior to embedding, aortic rings were incubated with fluorescently 
labeled low-density lipoprotein (Biomedical Technologies) for a small subset of samples.  
These explants were imaged with fluorescent microscopy to confirm that cells 
participating in tube formation were endothelial in nature.      
 To embed the explants, 200 µl of 1.5 mg/ml rat tail type I collagen (Serva 
Chemical) was initially pipetted into the bottom of each agarose well and placed into the 
incubator for 15 minutes to polymerize.  Then, an aortic segment was placed on top of 
each of these collagen layers and covered with another 200 µl of type I collagen.  After 
allowing the second collagen layer to gel for 15 minutes in the incubator, 6 mLs of 
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MCDB-131 containing 25 mM NaHCO3, 2.5% autologous mouse serum, 1% glutamine, 
and penicillin/streptomycin was added to the dish.  Explants were imaged 
microscopically at 4, 6, 8, and 10 days, and the number of vascular sprouts and length of 
the largest sprout from each aorta were measured.        
Monocyte/Macrophage Migration Assay 
Cell culture transwell chemotaxis inserts (Falcon) with a pore size of 8 µm were 
coated overnight at 4°C with 10 µg/ml fibronectin (Sigma) and then allowed to air dry.  
Resident monocytes and macrophages were isolated from wild type and OPN deficient 
mice by peritoneal lavage with cold PBS.  Harvested cells were centrifuged, resuspended 
in 0.2% BSA, and counted using a Coulter counter.  720 µl of DMEM was placed in the 
lower well, and cells were seeded onto the tops of the inserts (400,000 cells per transwell) 
in 200 µl of DMEM.  Dishes were placed into the incubator, and the cells were allowed 
to adhere for 1 hour.  At this time, 80 µl of blank media or media containing 
chemoattractants were added to the lower reservoirs of the appropriate wells to reach a 
total volume of 800 µl with a final concentration of 5% homologous serum, 100 ng/ml 
MCP-1 (R&D systems), or negative controls with no stimulus (no stim).  After 
incubation for 8 hours, non-migrated were removed from the top of the membrane using 
cotton swabs.  Then, the remaining migrated cells were stained with Diff-Quick and 
imaged using brightfield microscopy.  Cell numbers were quantified from three random 





Micro-CT Imaging of Collateral Vessels 
 Micro-CT Imaging was completed at 7 days post surgery as a quantitative, 
anatomical measure of collateral vessel formation.  Qualitative observation of the 3-D 
image reconstructions of the vasculature of the ischemic limbs showed decreased 
collateral blood vessel formation in upper thigh region of the OPN deficient mice relative 
to the wild types as shown in Figure 4.2 A.  Quantitative analysis of these specimens 
determined that the OPN knockouts possessed significantly reduced vascular volume of 
the ischemic limb (Figure 4.2 B).  We also completed a size discriminated measurement 
on what we deemed to be newly formed collaterals, which were defined as vessels with 
diameter less than or equal to 180 microns.  When we completed this focused analysis, 
we found that the OPN deficient animals possessed significantly decreased vascular 
volume relative to the wild types, indicating that the difference in total vascular volume 
was primarily driven by a lack of smaller, newly formed collateral-sized vessels  (Figure 












































































































































































Figure 4.2.  Micro-CT image analysis.  (A) Micro-CT images showing decreased collateral 
vessel formation in OPN deficient mice.  (B) Quantitative analysis shows significantly 
decreased vascular volume in OPN deficient mice.  (C) Relative volume of vessels less than 
or equal to 180 microns in diameter illustrates the defect in formation of small, collateral 
vessels in OPN deficient mice.  Data presented as mean+SEM.  n=7 for all analyses.  




Laser Doppler Perfusion Imaging 
 LDPI was performed to test for recovery of distal perfusion to the ischemic limb 
3, 7, and 14 days post surgery.  The acquired images illustrated a gradual recovery of 
perfusion to the paw for both genotypes, with a visible lag in recovery seen in the OPN 
deficient mice (Figure 4.3 A).  After calculation of average perfusion in the ischemic paw 
relative to the contralateral paw, we found both genotypes to have only approximately 
25% perfusion by 3 days.  However, by 7 days post surgery, the wild types resting 
perfusion values were at about 70% of normal, while the OPN mice were significantly 
lower at around 40%.  At 14 days, this significant deficiency in perfusion recovery was 
even more pronounced, with wild types having nearly normal perfusion (88%) while the 
OPN knockouts possessed a persistent blood flow defect (45%).  See Figure 4.3 B. 
Swim Endurance Test 
As a functional measure of ischemic limb recovery, exercise capacity was 
measured 5 days post surgery.  At this time point, these mice, which had undergone one 
week of training prior to surgery, were forced to swim against a generated current until 
failure.  Using this metric, it was determined that the OPN deficient mice had 
significantly hindered function of the ischemic limb, as shown by a 40% decrease in 





























































Figure 4.3. LDPI analysis.  (A) Representative LDPI images display the time course of 
recovery of ischemic limb perfusion in OPN deficient and wild type mice.  Color-coded 
perfusion scale shown on right.  (B) Quantitative analysis (average perfusion in ischemic 
paw / average perfusion in normal paw) displayed a significant lag in recovery in OPN 
deficient mice.  Data presented as mean+SEM.  n=11-14 for each group.  * indicates 
significant differences (p<0.001) determined using Tukey’s method for pairwise 





































Figure 4.4.  Swim endurance test.  Relative to wild types, OPN deficient mice displayed 
significantly decreased swim endurance 5 days following onset of ischemia.  Data 






Aortic Ring Vascular Sprouting Assay 
 The aortic ring assay was utilized to measure endothelial cell angiogenic capacity 
through their ability to sprout/migrate into a collagen gel and form vascular tubes.  Wild 
type and OPN deficient aortic rings were harvested, embedded ex vivo in collagen gels, 
and assayed for neovascular sprouting every two days from 4-10 days.  These rings 
displayed substantial sprouting, which peaked at around 1 week and could be imaged 
using light microscopy.  There was a modest, but insignificant overall decrease in sprout 
number in OPN deficient specimens relative to wild types, and there was no difference 
between genotypes for maximum sprout length (Figure 4.5).   
Monocyte/Macrophage Migration Assay 
 Since movement of monocytes and macrophages to sites of angiogenesis and 
collateralization is suspected to be a pivotal early event in these processes, we evaluated 
migration of these cells in response to chemoattraction.  To do so, peritoneal 
monocytes/macrophages were harvested from wild type and OPN-/- mice and assayed for 
chemotaxis toward homologous serum and MCP-1.  Homologous serum produced a 
strong induction in monocyte/macrophage migration for both genotypes.  OPN-/- serum 
stimulated a significant increase (2.4-fold) in migration of OPN-/- cells.  Wild type cells 
displayed significant migration toward homologous serum (6.8-fold increase), which was 
also significantly greater than the chemotactic response of the OPN-/- cells to serum 
(Figure 4.6 A).  In OPN-/- cells, MCP-1 did not invoke significant migration above 
negative controls.  Wild type cells exposed to MCP-1, on the other hand, migrated 
significantly more than cells that were not exposed to chemoattraction or OPN deficient 














































































Figure 4.5.  Aortic ring sprouting assay. (A) Representative aortic ring specimens 
displayed that the OPN deficient specimens possessed a modest decrease in angiogenic 
sprouting at 8 days. (B) OPN deficient mice displayed a trend towards reduction in 
number of vascular sprouts and (C) no difference in maximum sprout length over a 10 
day time course.  Genotype was not found to be a significant predictor of sprout number 
or maximum sprout length using ANOVA, and, using Tukey’s method, it was determined 
that no significant differences existed in pairwise comparisons between genotypes for 













































































Figure 4.6.  Macrophage chemotaxis assay. OPN deficient mice displayed a significant 
quantitative reduction in number of monocytes/macrophages that migrated across the 
membrane in response to chemoattraction from (A) homologous serum or (B) MCP-1.  
Data presented as mean+SEM.  For each data point shown, n=12 (4 wells, 3 fields per 
well).  Post-hoc comparisons done using Tukey’s method.  † indicates significance 
(p<0.01) versus WT no stim and OPN no stim.  # indicates significance (p<0.0001) 
versus OPN serum.  * indicates significantly different (p<0.001) from WT no stim, OPN 
no stim, and OPN MCP-1.   
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Discussion 
Previous in vitro studies have discovered roles for OPN in controlling survival, 
migration, and other functions in multiple cell types involved in postnatal vascular 
growth.  In this study, we sought to determine the in vivo significance of OPN in 
angiogenesis/arteriogenesis processes.  To do so, we compared wild type and OPN-/- mice 
for their capacity to form collateral vessels and functionally recover following acute 
induction of hind limb ischemia.  Following ligation and excision of the femoral artery, 
OPN deficiency was found to significantly delay collateral vessel formation, restoration 
of distal limb perfusion, and recovery of the functional capacity of the ischemic limb.  
These in vivo observations were found to correlate to normal ex vivo endothelial 
sprouting.  In contrast, these results corresponded to a substantial decrease in migration 
of in vitro OPN-/- monocytes/macrophages in response to chemoattraction.  These data 
suggest that OPN is a critical regulator of collateral vessel formation and that this effect 
is driven by its role in mediating monocyte/macrophage migration and functionality.   
The initial endpoint of our study was based on quantitative 3-D micro-CT 
imaging methodologies that were established in our lab (130).  Using this technique, we 
are able to perform high resolution, objective, and quantitative measurements of the 
global vascular anatomy within the mouse hind limb to a degree not afforded by 
immunohistochemistry, X-ray angiography, or other commonly utilized methods.  
Importantly, using this modality, we were able to detect significantly decreased total 
vascular volume, which was driven by a decrease in smaller, collateral-sized vessels in 
OPN deficient mice.  Next, we utilized the LDPI imaging methodology as a measure of 
blood flow to evaluate the physiological significance of this finding.  LDPI is a 
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commonly used endpoint in mouse hind limb ischemia studies, and it has been found to 
correlate with histological vessel counting (107).  Using LDPI, we performed 
measurements on anesthetized mice and found decreased recovery of perfusion to the 
ischemic paw in the OPN-/- mice at both 1 and 2 weeks post surgery.  In addition, we 
measured the exercise capacity of the mice as a means for functional assessment of 
ischemic limb recovery.  We felt that it was especially important to run this full 
complement of studies to correlate vascular anatomy and blood flow to limb 
functionality, considering previous reports have indicated that measuring resting blood 
flow does not always accurately reflect the true flow deficit in animal models of hind 
limb ischemia (116).  In order to measure limb functionality, we built a swimming 
apparatus that forced the mice to swim against a generated current (220).  This technique, 
unlike treadmill tests, requires that the mice equally utilize both of the hind limbs and 
provides a useful methodology for measurement of exercise endurance and, therefore, 
functional recovery of the ischemic leg.  Using this apparatus, we were able to measure a 
significant functional impairment of the ischemic limb in the OPN-/- mice relative to the 
wild types at 5 days post surgery.  Taken together these data indicate an unequivocal role 
for OPN in revascularization and recovery from hind limb ischemia.  
Endothelial cell function is generally considered to be of the utmost importance 
for neovascularization.  Therefore, in order to better understand our in vivo findings, we 
first sought to assess the capacity for endothelial cell tube formation in aortic explants 
from OPN deficient mice.  To do so, we employed the aortic ring vascular sprouting 
assay, which allows controlled measurement of neovascular sprouting from an intact 
vessel segment containing the full complement vessel constituents (96).  In this study, 
 87
OPN null specimens showed trends toward decreased sprout number, but no significant 
differences were detected between genotypes for sprout number or maximum sprout 
length.  These results indicate that OPN may not play a vital role in endothelial cell 
migration and tube formation during angiogenesis.   However, this assay is limited by the 
fact that it measures the angiogenic response of the aortic endothelium rather than that of 
the microvasculature, which participates in the in vivo neovascularization process. 
It is well-accepted that monocytes/macrophages bind to the vascular wall and 
localize to sites of angiogenesis and arteriogenesis where they play an important role in 
modulation of these processes (6).  This finding dates back 30 years to the observation by 
Shaper et al. that large numbers of monocytes adhered to the endothelium and passed into 
the vessel wall of forming collaterals in the dog heart (40).  Subsequent studies have 
shown a direct functional link between circulating monocyte concentration and 
arteriogenic collateral vessel formation (42,43).  MCP-1 is thought to be the primary 
stimulus for induction of monocyte infiltration in this setting, and MCP-1 treatment has 
been shown to accelerate collateralization and recovery in hind limb ischemia models in a 
variety of animal studies (44,47-53).  Conversely, animals deficient in MCP-1 or CCR2-
chemokine receptor, an MCP-1 receptor, have been shown to display reduced 
monocyte/macrophage infiltration and collateral formation (54,55).   
These studies have established monocyte and macrophage migration to the site as 
a pivotal event in ischemic limb revascularization and recovery.  In addition, previous 
work has indicated that OPN helps to mediate macrophage adhesion and migration, and 
other studies have indicated that OPN may be important for macrophage infiltration to 
sites of injury in vivo (178).  Due to this established connection between OPN and 
 88
macrophage migration, we hypothesized that OPN would play a role in macrophage 
infiltration and function at sites of postnatal vascular growth.  In order to test this 
hyposthesis, we compared macrophage/monocyte migration capacity of wild type and 
OPN deficient mice.  To do so, we utilized the transwell cell culture system to evaluate 
the migratory response of monocytes/macrophages that were isolated using peritoneal 
lavage.  In these studies, we found that OPN-/- monocytes/macrophages displayed 
significantly reduced migration in response to chemoattraction.  In initial experiments, 
we found that wild type cells exhibited a 3-fold stronger migratory response to 
homologous serum than OPN-/- cells.  Next, we evaluated whether this defect in 
migration would be sustained using an OPN-free chemotactic stimulus, MCP-1.  MCP-1 
induced significant migration of wild type cells relative to controls (1.7-fold), but the 
response was not as strong as it was to serum.  Importantly, as seen in the experiments 
using serum, this response was significantly higher than the OPN-/- cells, which did not 
display any significant migratory response to MCP-1 relative to cells exposed to no 
chemoattraction.  These findings corroborate a previous study that found OPN to be 
important to chemotactic response of macrophages to MCP-1 in vitro (221).  This 
experiment indicates that the migratory defect in the OPN-/- monocytes/macrophages is 
not dependent upon stimulation from exogenous OPN alone and that this response is 
driven at least in part by autocrine OPN stimulation.   
The significance of our in vitro findings showing decreased migration of OPN-/- 
mononctyes/macrophages toward MCP-1 is strengthened by the fact that MCP-1 has 
been shown by numerous studies to play an important role in in vivo stimulation of 
monocyte homing and activity at sites of collateralization.  It is believed that once these 
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cells have arrived at the site of angiogenesis/arteriogenesis, they produce growth factors 
and proteases that induce vascular endothelial and smooth muscle cell proliferation and 
stimulate remodeling of the vascular wall in order to satisfy increased blood flow 
demands.  In addition to providing paracrine stimulation of other cells types, monocytes 
have also been reported to tunnel through ischemic myocardium and form physical 
conduits that could be subsequently endothelialized and incorporated into the preexisting 
vasculature (222).  Therefore, defective migratory response to chemoattraction and the 
subsequent reduction in activity of monocytes and macrophages at the site of 
collateralization likely has significant, detrimental effects on revascularization and 
recovery of the ischemic limb in the OPN-/- animals. 
In this study, we have presented evidence suggesting that a definitive biological 
role exists for OPN in the vascular response in the mouse hind limb ischemia model.  We 
were able to confirm this finding using a range of anatomical, physiological, and 
functional measurements on the ischemic limb.  We have also reported evidence that 
suggests that this defect in angiogenesis/arteriogenesis could be driven by alterations in 
macrophage migration and function in the OPN null mice.  These findings represent the 
first evidence that OPN may be a key regulator for postnatal vascular growth and that 
OPN may be an important mediator of macrophage function in this setting.    
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CHAPTER 5 
IMPAIRED ANGIOGENESIS, EARLY CALLUS FORMATION, AND 
LATE STAGE REMODELING IN FRACTURE HEALING OF 
OSTEOPONTIN DEFICIENT MICE 
Introduction 
Bone fracture healing involves a well-characterized cascade of events that 
includes hematoma formation, inflammation, soft cartilaginous callus formation, 
neovascularization, osteoblastic callus mineralization, and osteoclastic remodeling of the 
hard callus back to mature lamellar bone (144).  This complex sequence of biological 
processes is orchestrated by a variety of growth factors and matricellular proteins that 
regulate differentiation, chemotaxis, and haptotaxis of the cell types responsible for 
mediating these events.  For example, the family of BMPs has been thoroughly 
characterized for induction of osteogenesis at fracture sites and is utilized clinically to 
promote bone regeneration (147).  In addition, Street et al have shown that VEGF, a 
known promoter of angiogenesis, stimulates neovascularization and promotes fracture 
healing, while treatment with angiogenesis inhibitors that specifically target vascular 
cells blocks fracture healing and produces atrophic nonunions (151,152).  Furthermore, as 
reviewed by Alford et al., ECM proteins, while not always vital for normal embryonic 
bone development, play an important role in mediating cellular function and serve as 
important modulators of bone regeneration (154).  Further understanding of the intricate 
interplay between this diverse set of cell types, endogenous factors, and matrix proteins is 
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a necessity for the development of improved therapeutic strategies for promoting bone 
repair. 
 Osteopontin is one of the major non-collagenous ECM proteins in bone.  It has 
been studied based on its role in a diverse range of biological processes including 
inflammation, immunity, angiogenesis, wound repair, tumor formation and metastasis, 
cellular survival and migration, and osteoclastic bone remodeling.  Although now known 
to also be present in a number of nonmineralized tissues, OPN was originally cloned 
from bone where it has been shown to have a functional role in controlling mineralization 
and remodeling.  OPN inhibits mineral crystal formation and growth (188,189), and OPN 
deficient mice have been found to possess increased mineral content and crystallinity 
(190).  In addition, OPN is known to be a major ligand for CD44 on bone cells, which is 
important in mediating osteoclast recruitment and function (187,191,192).  The in vivo 
importance of OPN in bone remodeling has been further demonstrated by the finding that 
OPN deficient mice undergo significantly less bone resorption than wild type mice in 
response to reduction in mechanical loading, ovariectomy, stimulation by parathyroid 
hormone, or administration of a high phosphate diet (193-196).   
While many researchers have studied the role of OPN in bone, it is also important 
for normal arterial physiology (173) and is produced by the primary cell types involved in 
blood vessel growth and remodeling: monocytes/macrophages, endothelial cells, and 
smooth muscle cells (174).   In addition to its interactions with CD44, OPN also contains 
an RGD motif, which allows it to interact with the integrin family of cell-adhesion 
molecules including α4β1 (158) and αvβ3 (176).  Previous in vitro studies have 
demonstrated that cellular interactions with OPN mediated through these integrins 
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regulate a wide variety of cellular functions relevant to angiogenesis including vascular 
cell adhesion and spreading (179), macrophage adhesion and migration (178), endothelial 
cell migration (176), endothelial cell survival (175), chemotactic response of smooth 
muscle cells (179), and smooth muscle cell migration (180).  Other in vivo studies have 
also implicated OPN in neovascularization and remodeling of the vessel wall.  For 
example, OPN mRNA has been shown to be locally upregulated at the site of ischemia-
induced retinal neovascularization in mice (3), and OPN deficiency has been found to 
decrease angiogenesis around ectopic bone implants and to diminish arterial remodeling 
(2,173).  Based on these observations, it is likely that the vascular effects of OPN are also 
relevant to vessel formation and maturation during fracture healing.   
The role of OPN in a diverse set of processes including macrophage function, 
angiogenesis, ECM mineralization, and osteoclastic bone remodeling suggests that OPN 
may be important during multiple stages of fracture healing.  Previously, in situ 
hybridization studies have noted OPN expression in the fracture callus by 
osteoprogenitors in woven bone, hypertrophic chondrocytes in the cartilage to bone 
transitional region, and in the osteocytes, osteoblasts, and osteoclasts of the hard callus 
(144,197,198).  However, the specific function of OPN during bone healing has not been 
previously determined.  In the present study, we hypothesized that OPN deficiency alters 
neovascularization, mineralization, remodeling, and the restoration of mechanical 
properties during fracture healing.  To test this hypothesis, we have investigated fracture 






Male wild type C57BL/6 mice were purchased from the Jackson Laboratory.  
Osteopontin deficient mice were originally received from Dr. Lucy Liaw of the Maine 
Medical Center (170), and they were subsequently back-crossed ten generations onto the 
C57BL/6 background.  All animals were fed a standard chow and had free access to 
water.  All protocols were approved by the Institutional Animal Care and Use Committee 
and done in accordance with the federal guidelines on the principles for the care and use 
of animals in research.    
Intact Bone Biomechanics 
The baseline biomechanical consequence of OPN deficiency in intact bone was 
assessed by testing femora from 10-week-old wild type (n=5) and OPN-/- (n=7) mice.  
Soft tissues were removed, and the bones were wrapped in PBS soaked gauze and frozen 
at –20°C.  The left femora from these mice were tested in three-point bending, and the 
right femora were testing in torsion.  All bones were thawed in PBS at room temperature 
for 3 hours prior to mechanical testing.  While thawing, the specimens were imaged using 
the VivaCT 40 micro-CT imaging system (Scanco Medical) at a voxel size of 21 µm.  
The micro-CT images were utilized to determine moment of inertia within the mid-
diaphyseal region, which was used to calculate bone material properties.   
For three point bending tests, specimens were loaded onto a three-point bending 
setup with a 6.2 mm distance between lower supports.  An 858 Mini Bionix II testing 
system (MTS) was then used to load the femora to failure at a rate of 0.05 mm/sec with 
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the anterior side in tension and posterior side in compression.  Maximum load, elastic 
modulus, work to failure, and post yield displacement were determined from the recorded 
force-displacement data.   
For torsional testing, we designed fixtures and a custom potting apparatus that 
allowed us to reproducibly align and pot the femora in Wood’s metal with a gauge length 
of 6.5 mm.  After the femora were potted, they were loaded in torsion at a rate of 3 
degrees per second until failure using an ELF 3200 testing system (Bose Corp.).  Using 
the recorded test data, maximum torque, shear modulus, work to failure, and post yield 
rotation were determined.   
Bone Fracture Healing Model 
 A well-established, unilateral femoral fracture model (4) was utilized to study 
bone repair in 10-week-old male wild type and OPN-/- mice.  Animals were anesthetized 
by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (80 mg/kg).  All hair 
was removed from the surgical site, and the area was cleansed with sterile water followed 
by betadine.  A 25-gauge needle was inserted in a retrograde manner into the 
intramedullary canal of the right femur.  Subsequently, a mid-diaphyseal fracture was 
created in this leg, and the contralateral leg was left intact.  The mice were allowed to 
recover on a heated pad, and, after awakening, they were returned to their cages and 
allowed to ambulate freely.  Upon sacrifice, any animals that displayed intramedullary 
pin displacement, fractures that were not transverse, or fractures not in the mid-
diaphyseal region were removed from the study.   
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Micro-CT Analysis of Fracture Site Neovascularization 
Recently developed quantitative micro-CT based methods (130) were utilized for 
evaluation of fracture callus vascularity.  Mice were sacrificed using carbon dioxide 
inhalation at 7 days (wild type n=10, OPN-/- n=10) or 14 days (wild type n=9, OPN-/- 
n=6) post surgery.  The vasculature of the mice was sequentially perfused at physiologic 
pressure using heparinized (100 units/mL) normal saline, 10% neutral buffered formalin, 
and then again with heparinized saline.  The vascular system was then injected with a 
radiopaque, lead chromate based contrast agent (Flow Tech Inc.), which was then 
allowed to polymerize for 24 hours at 4°C.  The fractured femora were isolated from the 
surrounding musculature under a dissecting microscope, and the intramedullary pins were 
carefully removed.  The femora were stored at 4°C for 48 hours in 10% neutral buffered 
formalin, soaked 48 hours in a formic acid based solution for decalcification of the 
mineralized bone, washed thoroughly using water, and placed in 10% neutral buffered 
formalin until imaging.  The decalcification procedure is a vital step that allows 
radiodensity-based segmentation of the contrast-filled vessels from the surrounding 
mineralized tissues, and, therefore facilitates calculation of vascular morphology 
parameters.  The specimens were imaged at a 10.5 µm isotropic voxel size, and two-
dimensional (2-D) tomograms were reconstructed.  The volume of interest was defined 
by drawing contour lines along the borders of the callus in the 2-D slices.  Then, within 
this VOI, the 2-D images were globally thresholded based on x-ray attenuation and used 
to render binarized 3-D images of the radiopaque, contrast-filled vascular network 
segmented from the surrounding tissues.  These 3-D images were evaluated for vessel 
volume, volume fraction, and average diameter. 
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Micro-CT Analysis of Fracture Callus Formation and Mineralization 
 Mice were euthanized post-operatively for micro-CT imaging at 7 (wild type n=7, 
OPN-/- n=6), 14 (wild type n=7, OPN-/- n=6), 28 (wild type n=5, OPN-/- n=8), and 56 
(wild type n=7, OPN-/- n=6) days.  The femora were removed and dissected free from 
surrounding musculature under a dissecting microscope.  The intramedullary pins were 
removed, and the bones were wrapped in PBS soaked gauze and frozen at –20°C.  Upon 
removal from the freezer, the bones were placed in PBS to thaw at room temperature.   
While thawing in PBS, the specimens were imaged using micro-CT at a voxel 
size of 21 µm.  The newly formed fracture callus tissue was spatially segmented from the 
native cortical bone in the 2-D tomograms.  Prior to generation of 3-D images of the 
mineralized callus, we scanned a set of hydroxyapatite (HA) phantoms (0-800 mg HA) in 
order to define our mineralization threshold.  Based on the precedent set in a similar 
fracture healing study (151), we defined the fracture callus mineralization threshold (295 
mg HA/cm3) as 50% of the mineral density that we utilized to segment intact cortical 
bone.  Using this threshold, three-dimensional images of the mineralized callus were 
rendered, and total volume, percent mineralization, and average mineral density were 
measured on the digitally extracted callus tissue.   
Fracture Specimen Biomechanical Testing 
Specimens were thawed in PBS at room temperature for a total of 3 hours prior to 
mechanical testing, during which time micro-CT imaging was completed as discussed 
above.  For three-point bending tests, a pilot set of 28 day post fracture specimens were 
loaded onto a three-point bending setup as described for intact bone biomechanics (wild 
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type n=8, OPN-/- n=8).  Ultimate load, work to maximum load, and displacement at 
maximum load were determined from the recorded force-displacement data.  
For torsional mechanical testing, the fracture calluses were loaded to failure using 
the same testing setup described for intact bone biomechanics.  Stiffness, yield point, 
maximum torque, work to failure, rotation at failure, and post yield rotation were 
determined for the fracture specimens.  Specimens collected at the earliest time point (7 
days) were too fragile to test, so this analysis was only completed on specimens 14, 28, 
and 56 days post fracture (14 days wild type n=7, OPN-/- n=6; 28 days wild type n=5, 
OPN-/- n=8; 56 days wild type n=7, OPN-/- n=6). 
Real-time RT-PCR 
 RNA was isolated from the mid-diaphysis of intact bones and from fracture callus 
tissues at 3, 7, and 14 days post surgery.  The tissue was snap frozen and homogenized in 
QIAzol lysis reagent (Qiagen).  RNA was purified using a commercial kit (Qiagen) and 
then reverse transcribed into cDNA using the SuperScript™ III First Strand Synthesis 
System (Invitrogen), which was subsequently purified using a commercially available kit 
(Qiagen).  Primers were designed using the ABI Primer Express software (Table 5.1), and 
SYBR Green intercalating dye (Applied Biosystems) was used to perform real time PCR 
with the ABI Prism 7700 Sequence Detection System (Applied Biosystems).  Standards 
for each gene were amplified from cDNA and purified.  Standard concentrations were 
determined using spectrophotometric measurement at 260 nm, and standards were 
serially diluted to an appropriate range of concentrations.  Transcript concentration in 
template cDNA solutions was quantified from the linear standard curve and expressed as 
10-18 moles of transcripts per µg of total RNA. 
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Table 5.1. Oligonucleotides for quantitative RT-PCR 
 
Target Gene (Accession No.) Sense Primer Antisense Primer 
Osteopontin (AF515708) 5’-CCCTCGATGTCATCCCTGTT-3’ 5’-CCCTTTCCGTTGTTGTCCTG-3’ 
Fibronectin (M18194) 5’-TCTCGGAGCCATTTGTTCCT-3’ 5’-TTGTCACAGCGCCAGCC-3’ 
Bone Sialoprotein (L20232) 5’- TCCTCCTCTGAAACGGTTTCC-3’ 5’-GGAACTATCGCCGTCTCCATT-3’ 
Col1α1 (U08020) 5’-TGGATTCCCGTTCGAGTACG-3’ 5’-TCAGCTGGATAGCGACATCG -3’ 
Lysyl Oxidase (NM_010728) 5’-TAGCGAAGCACATAGCATTG-3’ 5’-TGCAGCAATGAGTCTACAGC-3’ 
Col2α1 (NM_031163) 5’-CCAGGGCTCCAATGATGTAGAG-3’ 5’- TGTTTCGTGCAGCCATCCT -3’ 
Col10α1 (NM_009925) 5’-CAAGCTCATCCTATTCTCCGCT-3’ 5’-CCAAATGCATCTCCAGGGA-3’ 
Osteoprotegerin (U94331) 5’-GAAAGCAGCGTGCAGCG-3’ 5’-TCAAGGCAAGAAGCTGCTCTG-3’ 
RANKL (NM_011613) 5’-GGATGTGGCCCAGCGAG-3’ 5’-GCAGCATTGATGGTGAGGTG-3’ 
TRAP (AK008391) 5’-CAGCCCAAAATGCCTCGA-3’ 5’-GCTTTTTGAGCCAGGACAGC-3’ 




 Mice were perfused with heparinized 0.9% normal saline, followed by 10% 
neutral buffered formalin.  Tissues were decalcified using a formic acid based agent (Cal-
Ex II, Fisher Scientific), embedded in paraffin, and cut into 5 µm thick longitudinal 
sections.  Images shown are representative of sections taken from n≥4 different animals.  
Immunostaining was done with antibodies to OPN (Immuno-Biological Laboratories), 
fibronectin (Chemicon), and bone sialoprotein (University of Iowa Developmental 
Studies Hybridoma Bank).  Primary antibodies were detected using an avidin-biotin-
alkaline phosphatase method from a commercially available kit (Vector Laboratories), 
and the sections were counterstained with hematoxylin.  Using commercially available 
kits (Sigma-Aldrich), safranin O staining was completed for detection of cartilage, and 
multinucleated osteoclasts were identified based on staining for tartrate resistant acid 
phosphatase (TRAP).   
Picrosirius red staining was done using standard methods (223).  Briefly, 
specimens were deparaffinized, rehydrated, stained for 1 hour in 0.1% sirius red F3B in 
saturated picric acid, washed in 0.5% acetic acid, dehydrated, cleared in xylene, and 
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mounted for imaging using planar polarized light microscopy.  Samples were aligned 
approximately 45 degrees from the transmission axis of the polarizing filters in order to 
maximize brightness of the images from each sample and provide a consistent 
assessment.  Using this technique, one can qualitatively assess collagen fiber organization 
based on polarization color (224).   
Measuring Total Collagen Content 
For analysis of total collagen content, the hydroxyproline assay (225) was 
performed on fracture calluses.  Briefly, the tissue was lyophilized and dry weight 
measurements were recorded.  The samples were decalcified in 10% formic acid, diced 
into small pieces, digested in proteinase K, hydrolyzed in 6N HCl at 110°C, and assayed 
for hydroxyproline content using a standard colorimetric assay (225).  
Statistical Analysis 
 All data are presented as mean ± SEM.  Statistical analyses were performed using 
the Minitab software.  ANOVA was used to model the effect of genotype on all response 
variables.  P<0.05 was interpreted as significant in all analyses. 
Results 
Intact Bone Biomechanics 
To determine the baseline biomechanical phenotype in intact bone, we tested two 
matched sets of intact wild type and OPN-/- femora in torsion and in three-point bending.  
We found consistent results for the two testing methods, confirming that OPN-/- bones 
possessed higher elastic/shear modulus, lower maximum load/torque, and reduced work 
to failure and post yield deflection/rotation (Table 5.2).    
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Table 5.2.  Intact bone mechanics.  Comparison of wild type (n=5 for both testing 
setups) and OPN deficient (n=7 for both testing setups) intact bone properties.  
ap<0.05, bp<0.005. 
 
 3-Point Bending Torsion 
 WT OPN-/- WT OPN-/- 
Modulus 3.82 ± 0.24 5.28 ± 0.12b 2.22 ± 0.15 3.02 ± 0.13b 
(GPa, GPa)   
Max Load / Torque 18.4 ± 0.8 16.3 ± 0.3a 31.9 ± 2.9 21.5 ± 0.7b 
(N, N-mm)   
Work to Failure 14.7 ± 2.1 8.8 ± 0.5a 327 ± 17 167 ± 9b 
(N-mm, N-mm-deg)   
Post Yield Displacement 1.01 ± 0.61 0.61 ± 0.06a 14.5 ± 1.3 8.9 ± 0.7b 
(mm, degrees)   
 
 
Expression and Immunolocalization of ECM Proteins in OPN-/- mice 
Quantitative RT-PCR measurement of OPN expression in wild type and OPN-/- 
intact and fractured femora at 3, 7, and 14 days post-surgery illustrated increased OPN 
expression in the setting of fracture healing in the wild type animals.  In addition, it 
validated the complete absence of OPN mRNA in the knockout animals.  
Immunohistochemical staining of 28 day post surgery tissue sections taken from the 
fracture callus corroborated this finding, illustrating the lack of OPN at the protein level 
in the knockout animals and the localization of OPN in the fractured wild type bones 
(Figure 5.1). 
It has been hypothesized that the relatively mild bone phenotype seen in OPN-/-
mice without external stimulation could be due to compensatory activity of other, similar 
ECM proteins.  Here we measured the gene expression and protein localization of 
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fibronectin and bone sialoprotein (BSP), two bone ECM proteins that possess similar 
recognition sequences and properties to OPN.  These genes displayed intense upregulation 
in fractures relative to intact bones for both genotypes, but, other than a significant but 
modest deficiency in BSP expression at 14 days, we found that OPN deficient mice 
displayed no aberrant expression of these genes relative to the wild type animals.  Using 
immunohistochemistry, we further observed apparently normal localization of these related 























OPN-/- NO FX OPN-/- FX WT NO FX WT FX
 
Figure 5.1.  Validation of OPN deficiency and evidence that no compensatory changes in 
gene expression or protein localization of bone sialoprotein and fibronectin occur in OPN-/- 
mice.  (A) Quantitative RT-PCR measurement of OPN, BSP, and FN expression in OPN 
deficient and wild type (WT) intact (No Fx) and fracture healing (Fx) bone samples 3, 7, 
and 14 days post-surgery expressed as 10-18 moles of transcripts per µg of RNA (ap<0.05). 
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Figure 5.1  (B) Representative immunohistochemistry photomicrographs of the fracture 
sites from WT and OPN deficient mice identifying OPN at 28 days post fracture and BSP 
and fibronectin at 14 days post fracture.  These data illustrate increased OPN expression in 
the setting of fracture healing and the absence of OPN mRNA in the knockout animals, in 
addition to the lack of OPN at the protein level in the OPN-/- mice and the localization of 
OPN in the wild types.  BSP and fibronectin were upregulated in the setting of fracture 
healing, and, other than a modest decrease in BSP expression in OPN-/- fractures at 14 
days, no alterations were seen in gene expression or protein quantity or localization of 
these ECM proteins in the fracture callus due to OPN deficiency.  
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Micro-CT Analysis of Fracture Site Neovascularization 
We utilized micro-CT imaging of contrast perfused, decalcified specimens for 
visualization and quantification of vascular growth within the fracture callus (Figure 5.2 
A).  Significantly reduced vessel volume and vessel volume fraction, along with a trend 
toward decreased average vessel diameter (p=0.071), were detected in the fracture 
calluses of OPN-/- mice compared to wild types at 7 days post surgery (Figure 5.2 B).  At 
14 days post surgery, while there was a significant reduction in average vessel diameter 
in OPN-/- mice, significant differences for other vascular parameters were no longer 
present (Figure 5.2 C).   
Micro-CT Analysis of Fracture Callus Formation and Mineralization 
Micro-CT imaging was utilized to measure volume, percent mineralization, and 
average mineral density within the newly formed fracture callus that was outside the 
periphery of the pre-existing cortical bone structure (Figure 5.3 A).   The OPN-/- mice 
displayed a significant reduction in callus volume relative to the wild types at days 7 (-
27%) and 14 (-30%).  No differences were seen in callus volume between genotypes at 
28 days, and callus volume was significantly increased (46%) in the OPN deficient mice 
compared to wild types at 56 days post fracture (Figure 5.3 B).  The OPN-/- mice 
displayed accelerated early mineral formation and had significantly higher percent callus 
mineralization at 14 days.  However, no differences were seen in percent callus 
mineralization at other time points (Figure 5.3 B).  Lastly, the average density of the 
mineralized portion of the fracture callus was significantly lower in the OPN deficient 
mice at 28 days, and this trend persisted but was no longer significant at 56 days (Figure 























































Figure 5.2.  Reduced early stage neovascularization in OPN deficient mice was 
recovered at later time points.  (A) 7-day and 14-day post surgery micro-CT images 
visibly showed reduced early neovascularization in OPN deficient mice that appeared to 
be recovered by 14 days.  (B) At 7 days, this angiogenic deficiency was found to be 
significant in quantitative 3-D image analyses of vascular volume and volume fraction 
(wild type n=10, OPN-/- n=10).  (C) At 14 days post surgery, micro-CT images and 
quantitative analysis revealed reduced average vessel diameter but an overall recovery of 
the early vascular defect seen in the OPN deficient mice (wild type n=9, OPN-/- n=6).  
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Figure 5.3.  OPN deficient mice displayed reduced early stage callus size, increased early 
mineralization, and delayed late stage remodeling.  (A) Micro-CT imaging captured the 
time course of mineralized callus formation and remodeling in the wild type and OPN-/- 
mice.  (B) Quantitative image analysis revealed that OPN-/- mice possessed reduced callus 
size 7 and 14 days post surgery but increased callus volume 56 days post surgery.  OPN-/- 
mice also displayed increased percent callus mineralization at 14 days.  Analysis of average 
mineral density within the newly formed callus found that this parameter increased 
significantly over time post fracture, and it was found that OPN deficiency resulted in a 
small but significant decrease in average mineral density at 28 days post fracture.  7-day 
(wild type n=7, OPN-/- n=6), 14-day (wild type n=7, OPN-/- n=6), 28-day (wild type n=5, 
OPN-/- n=8), and 56-day (wild type n=7, OPN-/- n=6).  Scale = 1 mm.  ap<0.05, bp<0.005.  
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Fracture Specimen Biomechanical Testing 
In initial three-point bending tests done at 28 days post surgery, fractured OPN-/- 
femora displayed reduced deflection and work to ultimate load relative to wild types 
(data not shown).  However, in this pilot experiment, we found that the three-point 
bending setup resulted in artifacts from fracture callus indentation by the middle support.  
This affected the initial portion of the tests and made it difficult to accurately determine 
the stiffness and yield point, so, as a result, we switched to the torsional testing modality 
for biomechanical assessment.  Using torsional testing, we found that OPN-/- fractures 
possessed significantly reduced maximum torque at 14 and 28 days, but this difference 
did not persist at 56 days post fracture (Figure 5.4 A).  OPN-/- calluses required 
significantly less work to failure at 14 and 28 days post surgery (consistent with our pilot 
study using 3-point bending) but were similar to the wild types at 56 days (Figure 5.4 B).  
Furthermore, OPN deficient mice tended to have reduced post yield deformation at all 
time points, but ANOVA analysis did not find genotype to be a significant predictor 
(p=0.054) of this parameter (Figure 5.4 C).  Finally, stiffness was similar between 
genotypes at 14 and 28 days, but it was significantly higher in OPN-/- mice at 56 days 
post fracture, consistent with the observed increase in callus size at that time point 
















































Figure 5.4.  Altered fracture callus mechanics in OPN-/- mice.  OPN-/- mice had 
significantly reduced (A) maximum torque and (B) work to failure at 14 and 28 days post 
fracture.  The OPN deficient mice also showed a strong trend toward (C) decreased overall 
post yield deformation (p=0.054) as determined by ANOVA analysis and displayed (D) 
increased stiffness at 56 days.  14-day (wild type n=7, OPN-/- n=6), 28-day (wild type n=5, 
OPN-/- n=8), 56 day (wild type n=7, OPN-/- n=6). ap<0.05. 
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Gene Expression and Histology 
Cartilage Callus Formation 
Due to the reduction in fracture callus size at early time points, we hypothesized 
that the OPN deficient mice had defective development and hypertrophy of chondrocytes 
for formation of the early cartilaginous callus.  To test this hypothesis, we measured 
relative gene expression of type II and type X collagen, early and late markers of 
chondrocyte differentiation, respectively.  Quantitative RT-PCR measurement revealed 
that these genes were upregulated by 7 days post fracture, and there appeared to be a 
slight lag in chondrogenesis in the OPN deficient mice, which tended to have stronger 
persistence of cartilage markers at 14 days.  However, there was no significant difference 
in expression between genotypes (Figure 5.5 A), indicating that OPN deficiency does not 
significantly hinder chondrocyte formation and maturation at the fracture site.  Safranin 
O staining revealed similar staining patterns for the presence of cartilage in fracture 
callus sections from the two genotypes at 14 days post fracture, confirming this finding 
(Figure 5.5 B). 
Bone Remodeling 
Next, due to the larger residual fracture callus seen in OPN deficient mice at the 
latest time point, we hypothesized that OPN plays a critical role in osteoclastogenesis.  
To test this hypothesis, we first measured expression of RANKL and OPG, two of the 
most prominent proteins involved in regulation of osteoclast formation (226).  In 
addition, we measured expression of TRAP and Cathepsin K, two enzymes produced by 
mature osteoclasts to digest the mineralized bone matrix during remodeling.  Quantitative 
RT-PCR illustrated no significant differences in expression of these markers of 
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osteoclastogenesis between genotypes (Figure 5.6 A-B).  Furthermore, histological 
staining for TRAP activity indicated that the OPN deficient mice displayed similar levels 
of TRAP positive osteoclasts as their wild type counterparts at 28 days post fracture 
(Figure 5.6 C).  These data indicate that there is no defect in the basic machinery required 



















Figure 5.5.  Chondrocyte formation and maturation was not altered in the absence of 
OPN.  (A) Quantitative RT-PCR measurement of collagen II and collagen X, markers of 
chondrocyte formation and maturation, did not reveal differences in expression of these 
genes in the OPN deficient mice, indicating chondrogenesis was not altered in the 
absence of OPN.  Data are expressed as 10-18 moles of transcripts per µg of RNA.  (B) 
Safranin O staining confirmed normal cartilaginous callus formation at the fracture site in 
































Figure 5.6.  Osteoclast differentiation is not altered in the absence of OPN.  Quantitative 
RT-PCR (expressed as 10-18 moles of transcripts per µg of RNA) showed OPN deficient 
mice had no alteration in the expression of (A) OPG and RANKL, regulators of osteoclast 
maturation, or (B) cathepsin K and TRAP, markers of osteoclast activity.  (C) Staining for 
TRAP activity showed similar osteoclast number and activity in the OPN-/- mice compared 
to wild types.  These results suggest that osteoclast differentiation is not altered in the 
absence of OPN. 
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Type I Collagen Content and Organization  
OPN has been postulated to bind to other ECM proteins and to be important in 
matrix reorganization after injury (170).  Therefore, we measured gene expression of type 
I collagen, the most abundant bone ECM protein, and lysyl oxidase (LOX), an enzyme 
that cross-links collagen fibers.  Results indicated that these genes undergo rapid 
upregulation in the setting of fracture healing, but no differential expression between 
genotypes was detected (Figure 5.7 A).  In addition, we measured total collagen content 
at the protein level in 56-day post surgery fracture callus specimens as determined by the 
hydroxyproline assay.  At this late time point, the bony callus is primarily composed of 
type I collagen, but a well-known limitation of this assay is its inability to distinguish 
between different collagen types.  Based on this assumption, results indicated that total 
collagen content (collagen weight / total dry weight) in the fracture callus was not 
different between genotypes with an average of 12.7±0.3% for wild types and 12.3±0.3% 
for OPN-/- mice.  Next, we utilized picrosirius red staining combined with polarized light 
microscopy for qualitative determination of collagen fiber organization.  This imaging 
technique suggested that, while there is no difference in collagen content, the newly 
formed bone in the OPN deficient mice contained abnormal collagen organization 



























Figure 5.7.  Collagen I and lysyl oxidase expression was unchanged but collagen fiber 
arrangement was qualitatively different in OPN-/- mice.  (A) Quantitative RT-PCR 
measurement of type I collagen and lysyl oxidase was normal in OPN deficient mice as 
shown here expressed as 10-18 moles of transcripts per µg of RNA.  However, (B) polarized 
light microscopy of picrosirius red stained sections revealed a qualitative difference in 





In this study, we compared wild type and OPN-/- mouse femoral fracture callus 
formation, neovascularization, mineralization, and mechanical properties.  OPN 
deficiency was found to significantly alter but not prevent bone regeneration and 
remodeling of fractures in mice.  No compensatory overexpression of other ECM 
components was found, suggesting that there may be redundant mechanisms that allow 
fracture healing to occur (albeit delayed) in the absence of OPN due to common cellular 
binding sites (i.e. RGD sequence) and functional overlap between OPN and other ECM 
proteins.  Specifically, our data indicate that the presence of OPN is essential for normal 
early callus formation, neovascularization, and biomechanical strength and ductility.  
Additionally, OPN deficiency was found to delay the time course of remodeling of the 
fracture callus during the later stages of healing.  Lastly, while ECM content seemed 
generally unchanged, abnormal collagen organization was observed within the 
remodeling calluses of OPN-/- mice.   
At early stages of healing, OPN was found to play an important role in callus 
formation and to have a significant but transient effect on neovascularization.  The 
reduction in early vascular volume within the fracture callus at 7 days was recovered by 
14 days.  However, a significant decrease in average vessel diameter persisted indicating 
that OPN may also play a role in vessel maturation.  This may be related to the 
stimulatory role that OPN has on smooth muscle cell migration and chemotaxis 
(179,180), or it could be a consequence of the OPN-/- mouse macrophage phenotype, 
which has been linked to abnormal vascular remodeling (173).  Relevant to the latter 
hypothesis, OPN deficiency has been found to result in normal macrophage numbers but 
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decreased levels of macrophage activation in skin wounds, and intradermal injection of 
exogenous OPN has been found to stimulate macrophage infiltration (170,178).  The 
prior study was consistent with our findings, which indicated normal macrophage 
numbers (data not shown) but evidence that there may be defective functionality of these 
cells at the site of injury in the OPN-/- mice.  Therefore, in addition to the direct effects of 
OPN on endothelial and smooth muscle cell survival and migration, a reduced 
inflammatory response likely has secondary effects on callus neovascularization, vessel 
maturation, and ECM formation due to decreased reorganization of damaged tissue and 
cytokine production during the early stages of fracture healing.     
One interesting observation from this study is that, while the OPN-/- mice 
displayed a reduction in callus volume at 1 and 2 weeks post fracture, they possessed 
46% larger fracture calluses at 8 weeks.  The observed time dependent phenotype 
provides further evidence for the multifunctionality of OPN during fracture healing.  The 
increased residual fracture callus present in the OPN-/- mice at 56 days is likely due to the 
well-documented role that OPN has in mediating activity of mature osteoclasts during 
bone remodeling (187,191,192).  This defect, as was shown here, is not a result of 
inhibition of osteoclast differentiation or production of proteolytic enzymes.  Previous 
studies have also shown that osteoclastogenesis is not inhibited in the setting of OPN 
deficiency, and, in fact, a compensatory increase in osteoclast number has been reported 
in the bones of OPN-/- mice under basal conditions in some studies (191,194).  As 
elegantly shown by Chellaiah and co-workers, the reduction in functionality of OPN 
deficient osteoclasts can be attributed to decreased motility caused by a lack of cell 
surface expression of CD44 and activation of the αvβ3 integrin (191).   
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In the aforementioned study, Chellaiah and authors were the first to link OPN-/- 
osteoclast dysfunctionality to an observable in vivo bone phenotype in OPN deficient 
animals at baseline.  Although neither Rittling or Liaw found any abnormal bone 
phenotype upon initial development of the OPN knockout mouse (170,187), this group 
more recently reported larger femoral moment of inertia and, as determined by four-point 
bending, increased elastic modulus, ultimate moment, and energy to failure in OPN-/- 
mice (191).  In the present study, as verified using independent three point bending and 
torsional mechanical testing modalities, we found results that are partially contradictory 
to these previously published data.  Similar to Chellaiah et al., we observed an increase in 
the elastic modulus of OPN-/- bone.  However, the OPN deficient mice used for our study 
did not display increased femoral moment of inertia, and we found decreased maximum 
load and energy to failure relative to bones from wild type mice.  In addition, we found 
the OPN-/- mice to have an approximately 40% decrease in post yield deformation, a 
parameter that was not reported in previous studies.  Taken together, these biomechanics 
data indicate that OPN deficiency increases the material stiffness of the bone tissue and 
also causes it to be more brittle.  A few possible explanations exist for the discrepancy 
between our data and the previously published results.  The slightly older mice used in 
the Chellaiah publication could have displayed a phenotype that develops as the mice age 
due to a mild, but prolonged defect in osteoclast functionality.  These divergent results 
could also be a function of the difference in genetic background.  The previous study was 
completed with mice on a hybrid background, while the mice used here were backcrossed 
onto a C57BL/6 genetic background.  The potential relevance of this cannot be ignored 
considering the significantly dissimilar baseline bone phenotype between background 
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strains (227) and the different susceptibility of each mouse strain to a variety of 
pathologies including osteoporotic bone loss, femoral artery blockage, and 
atherosclerosis (228-231).  The final difference of note is that the mice used in our study 
were derived from the OPN deficient mouse population developed by Liaw et al., rather 
than the Rittling mouse.  The two different OPN knockouts were derived using slightly 
different methodologies, and the Rittling mouse has been found to express a small but 
likely non-functional fragment of the OPN protein (170,187).   
Significant functional effects of OPN deficiency were also evident in the 
biomechanical tests on the fracture callus specimens.  The physical significance of altered 
callus size was evident in the torsional tests, which showed that the smaller OPN-/- 
calluses at 14 days post fracture possessed significantly reduced maximum torque and 
work to failure.  Interestingly, significantly reduced mechanical properties (maximum 
torque, work to failure) were also found in the OPN deficient mice at 28 days post 
fracture, but no differences were seen in callus size or percent mineralization between 
genotypes at this endpoint.  These data, in addition to the strong overall trend toward 
decreased post yield behavior in the OPN-/- mice, indicate the existence of fracture callus 
material property differences as a result of OPN deficiency.  The observed brittle material 
behavior in the OPN-/- fracture specimens corroborates the observation of decreased 
ductility in OPN-/- intact bone, and this consistent decrease in bone quality may be the 
result of altered organization of the ECM within the callus of the OPN-/- mice.   The 
biological relevance of the callus volume was also evident at 56 days, at which point the 
OPN-/- specimens possessed significantly increased stiffness.  It should be noted, 
however, that at 56 days, the geometry of the fracture callus had undergone significant 
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remodeling in both genotypes and was relatively small compared to callus size 
measurements at earlier time points.  However, even at 56 days, it seemed that neither 
group had achieved a remodeling equilibrium or completely regained the mechanical 
properties of intact bone.  This incomplete restoration of bone quality can be readily 
explained by the fact that, while the bone geometry is approaching baseline, mineral 
density of the fracture callus has only reached approximately 60% of the mineral density 
of normal intact bone at this endpoint (data not shown).  
Despite alterations in size and biomechanical strength of the fracture callus, other 
than a modest change found in BSP mRNA levels, measurement of gene expression, 
immunohistochemical protein localization, and quantitative measurement of collagen 
content does not indicate compensatory changes in other ECM proteins in OPN-/- mice.  
However, while no differences were seen in total collagen content, picrosirius red 
staining suggested abnormal collagen organization within remodeling OPN-/- fracture 
calluses, which could be a result of alterations in collagen fibrillogenesis or turnover in 
OPN deficient mice.  This interpretation agrees with previous observations that OPN 
deficiency results in altered collagen fibril diameter and organization in skin wounds 
(170) and increased collagen maturity in bone (190).  Considering these observations, in 
conjunction with the fact that OPN has a high affinity for binding collagen (232), it is 
possible that the absence of an OPN-collagen interaction could result in aberrant fibril 
organization and contribute to the reduced mechanical integrity detected here for both 
intact and fractured OPN-/- bones.  Altered collagen organization may have a detrimental 
effect on the ability of the bone tissue to dissipate energy as mineralized fibrils begin to 
move relative to each other during post yield deformation of the tissue.  Consistent with 
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this interpretation, Hansma and co-workers have recently hypothesized that the 
mechanical behavior of bone is greatly influenced by nonfibrillar matrix proteins that 
form sacrificial bonds between mineralized collagen fibers.  They specifically suggest 
that OPN and related proteins may be important components of the “glue” that resists 
separation of collagen fibers and propagation of cracks during mechanical failure 
(233,234).  This recent work may provide a mechanistic explanation for both the 
alteration in collagen organization and the observed brittle behavior in the bones of the 
OPN-/- mice. 
In conclusion, OPN deficiency significantly alters several stages of the bone healing 
process but does not prevent bone union.  More specifically, this study indicates that 
OPN plays multiple roles during early callus formation, neovascularization, and late stage 
remodeling.  In addition, our extensive biomechanical analyses suggest that OPN 
functions to enhance bone strength and its ability to dissipate energy prior to failure.  The 
fact that no alterations in content of other ECM proteins were found suggests that the 
phenotype could be driven by altered matrix turnover and collagen organization, which 
appears to span multiple organ systems.  Therefore, we believe that a unifying link 
between the vascular and bone related defects found here may be related to diminished 
collagenous matrix organization and remodeling.  Hypothetically, this defect could 
decrease the ability of cells to bind to ECM and respond appropriately to environmental 
cues in the absence of OPN.  However, future studies are necessary to more definitively 
determine whether diminished ECM integrity is a primary effect of OPN deficiency or 
secondary to altered cellular functionality in the absence of OPN.  These findings 
contribute to an improved understanding of the role of OPN in vivo and provide new 
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insight into bone biomechanics and mechanistic control of vascularization and bone 
regeneration during fracture repair. 
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CHAPTER 6 
SUMMARY AND FUTURE CONSIDERATIONS 
Micro-CT Vascular Imaging 
 The micro-CT vascular imaging techniques developed in Aim 1 provided great 
utility in subsequent aims of this thesis project.  In addition, we have been able to 
collaborate with researchers within and outside of our institution to assist in 
implementation of this technique for a number of ongoing studies.  As discussed in detail 
in chapter 3, this technique has broad applicability to studies involving analysis of 
vasculature anatomy within small animal models.  However, some aspects of this 
methodology still have room for improvement.  
A continued obstacle during implementation of this technique is choosing the 
appropriate threshold value for vascular segmentation.  As mentioned, this part of the 
process is somewhat subjective, and choosing the appropriate global threshold involves 
balancing the tradeoff between omission of small vascular structures and overestimation 
of the larger vascular structures in the final 3-D images.  This tradeoff introduces artifacts 
into the quantitative analyses as well, since omission of small vessels has effects such as 
decreased vessel number, connectivity, etc, as shown in the threshold parameter 
sensitivity analysis in Chapter 3 (Figure 3.3).    In general, this technique provides a 
simple and useful platform for testing and implementation of micro-CT applications.  
However, many researchers have developed segmentation methods that are specifically 
designed for 3-D visualization of blood vessel networks.  Implementation of one of these 
algorithms may help to overcome some of the negative tradeoffs associated with global 
thresholding and thus yield more accurate 3-D renderings.   
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Over the past 15 years, dozens of new vascular segmentation algorithms have 
been developed, and these varied techniques have employed many different image-
processing strategies such as filtering, differential analysis, statistical methods, and even 
artificial intelligence concepts.  One example, which was specifically designed for 
improved segmentation of small diameter vessels, is the curve evolution for vessel 
segmentation (CURVES) algorithm (235).  CURVES falls into the deformable models 
category of segmentation methods and utilizes a “level-set approach” which determines 
the vessel axes before estimating their radii. The CURVES algorithm was primarily 
designed for segmentation of magnetic resonance angiography (MRA) images for use in 
pre-planning and performing image-guided neurosurgery, but this technique can be 
applied to 3-D CT data as well.  Figure 6.1 compares MRA vascular image segmentations 
using global thresholding and the CURVES algorithm.  Here, maximum intensity 
projection (MIP) images are shown as a standard with which to compare the binarized, 
segmented images.  MIP is a technique that depicts the brightest pixel value that is 
encountered along a viewing ray that travels through the stacked tomographic images.  
MIP is computationally fast, but the 2-D results do not provide a good sense of depth or a 
means for further 3-D computational analysis.  Figure 6.1 illustrates the increased 
capacity for resolving smaller caliber vessels using the CURVES algorithm, but also 
shows that this methodology introduces artifactual “thinning” of larger diameter vessels 
in MRA data.  However, this artifact does not persist in CT data due to differences in the 
nature of the vessel intensity profile between imaging modalities, and the authors 
exemplify this through an apparently more accurate segmentation of bronchi from a lung 
CT scan (Figure 6.2).  Incorporation of this or a similar vascular-specific segmentation 
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algorithm would improve the accuracy of the rendered 3-D images and subsequent 









Figure 6.1.  Comparison of global thresholding to CURVES algorithm for vascular 
segmentation.  Note that, compared to thresholding, the CURVES algorithm is able to 
better depict the connectedness and fine detail of the smaller vascular structures.  The 
authors note that the apparent “thinning” of the larger vessels is an artifact that occurs 











Figure 6.2.  CURVES algorithm segmentation of CT data from a lung scan.   Note that 
the artifactual thinning of the larger vessels does not occur in CT data since its intensity 
profile is not Gaussian.  Images modified from (235). 
 
 
Development of new in vivo contrasts and imaging techniques is another area with 
vast room for expansion in vascular micro-CT imaging.  Improvement in this area would 
grant the opportunity to perform longitudinal analyses within a given experimental 
animal.  This would allow for more information to be gathered from each experiment and 
spare animal lives and research time required to complete a given study.  Investigators in 
this area have concentrated on development of contrasts with longer circulation times 
based on slower clearance from the blood pool, allowing more time for imaging of the 
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anesthetized animal (237).  In our limited experience, these agents have provided 
insufficient contrast from surrounding tissues, but increasing the attenuation of the 
contrast or simply optimizing delivery to the circulation could make this a feasible 
methodology.  However, longitudinal in vivo scans on a single animal increase the 
amount of total X-ray exposure, and the potential biological effects of this amplified 
radiation dose must be considered.  Additionally, in vivo imaging would eliminate the 
possibility of decalcifying bone tissue, thus decreasing the ease of analyzing vascular 
networks in proximity to bone structures.  Therefore, as in vivo vascular contrasts and 
imaging techniques evolve, researchers must be cognizant of the new difficulties that 
may be encountered upon their implementation.  
Biological Functions of OPN 
 In chapters 4 and 5, we described studies that, for the first time, addressed the in 
vivo relevance of OPN for its role in postnatal vascular growth and bone healing.  As part 
of these studies, we utilized picrosirius red staining combined with polarized light 
microscopy to uncover an alteration in collagen fiber organization within the fracture 
calluses of OPN deficient mice.  In future work, it would be important to further 
understand this finding and to better determine the role of OPN in tissue remodeling 
following injury and for its contributions to normal and healing bone mechanics.  Along 
these lines, using electron microscopy and other mechanics techniques, one could provide 
valuable insights into the role of OPN in determining the ultrastructure of bone and other 
tissues and how this organization functionally affects the mechanical properties.   
As discussed in Chapter 5, we have found that OPN is an important contributor to 
post yield behavior, and OPN deficient bone was found to be more brittle in nature.  As 
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has been elegantly studied by Hansma and colleagues, sacrificial bonds or glue-like 
filaments are thought to bridge mineralized collagen fibrils and have substantial effects 
on the fracture resistance of bone (233,238-240).  As illustrated in Figure 6.3, these 
bridging molecules can be imaged with scanning electron microscopy (SEM) and their 
mechanical role can be measured with atomic force microscopy (AFM).  However, the 
constituents and nature of the sacrificial bonds between collagen fibrils remain unknown.  
As mentioned in Chapter 2, OPN possesses a high level of phosphorylation and thus, 
negative charge at physiologic pH.  As a result of its negative charge, OPN binds strongly 
to multivalent, positively charged ions such as calcium.  Due to this property, it has been 
hypothesized that OPN binds to the calcium ions within the hydroxyapatite component of 
mineralized collagen fibrils.  Based on this idea, OPN is suspected to be a prime 
candidate to participate in the “glue” between mineralized collagen fibrils in bone.  Using 
SEM and AFM techniques, comparison of wild type and OPN deficient bone specimens 
could further unravel the interactions of OPN with other ECM constituents and better 












Figure 6.3.  Visualization and mechanical measurement of glue-like filaments that resist 
separation of collagen fibrils.  (A) SEM images illustrating sacrificial bonds or “glue-like” 
filaments that bind together collagen fibrils and potentially resist their separation.  (B) 
Schematic depiction of these filaments resisting separation of collagen fibrils during 
propagation of a bone crack.  (C) Illustration of an AFM setup that can be used to measure 
the forces that resist mineralized collagen fibril separation in bone. (D) Graph displaying 
the contribution of sacrificial bonds to material properties by showing representative force 
measurements of a material with and without sacrificial bonds.  The slope of the force-
displacement recordings (dashed and dotted lines) show that these bonds can contribute to 
increased initial stiffness.  The shaded area between the recorded force-displacement data 
sets represents the significant enhancement of fracture toughness when sacrificial molecules 




As previously mentioned we postulate that altered ECM organization and 
remodeling across multiple organ systems could be the unifying characteristic that drives 
the bone and vascular phenotypes that we have found in the OPN null mice.  It has been 
previously reported that OPN deficient mice possess altered vascular ECM organization, 
which is apparent even at baseline (see Figure 6.4).  This study by Myers et al. also found 
that OPN knockouts displayed reduced remodeling of the vessel wall following carotid 
artery ligation, a defect that the authors attributed to altered ECM organization and 
reduced leukocyte invasion (173).  Many of the same mechanisms that control vascular 
remodeling in the pathological sense (i.e. neointima formation following vascular injury) 
also direct vessel formation and remodeling in more beneficial circumstances (i.e. 
revascularization of ischemic tissues).  To this end, in Chapter 4, we described findings 
that paralleled the results from the work of Myers et al.  This study indicated that OPN-/- 
mice also displayed delayed revascularization and functional limb recovery following 
onset of hind limb ischemia and reduced monoctye/macrophage chemotaxis.  We 
postulate that these in vivo hind limb ischemia results are a manifestation of a defect in 
arteriogenic vascular remodeling, a process thought to be mediated by monocytes and to 
be the most important contributor to reperfusion of ischemic tissues.  Likewise, in 
Chapter 5, bone fracture studies indicated that OPN deficiency resulted in diminished 
early neovascularization and a persistent decrease in vessel diameter, which could be 
further indicative of a role for OPN in vessel wall remodeling and maturation.  
 128
Figure 6.4.  Histological images displaying loosely organized collagen matrix in OPN 
deficient mice.  This observation is particularly evident in the adventitial layer and was 
found to result in increased vascular compliance and possibly contribute to reduced 
vascular remodeling following carotid artery injury.  Images borrowed from (173).  
 
  
Taken together, previous work and our own studies point to OPN playing an 
important role in formation and maintenance of organized ECM and in mediating 
monocyte/macrophage functionality.  However, it isn’t completely clear that these effects 
are primarily driven by the lack of OPN behaving as a structural component within the 
ECM.  For example, as mentioned previously, it was recently determined that interactions 
with an intracellular form of OPN plays an integral role in cell migration and activity of 
multiple cell types, including activated macrophages (167).  Therefore, it is also possible 
that the absence of OPN has a more direct effect on cellular functionality and that 
disorganized collagenous matrices in OPN-/- mice are a secondary effect of the cells’ 
ability to remodel and organize the ECM appropriately.   
 To gain insight into the functional importance of cell-mediated effects of OPN 
versus those due to ECM structural alterations, bone marrow transplant (BMT) studies 
could be performed.  In these studies, wild type bone marrow (BM) would be 
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transplanted into irradiated OPN-/- mice and vice versa.  After approximately 5 weeks are 
given for the donor BM cells to engraft into the irradiated recipient mice, this procedure 
would yield two sets of experimental animals.  One set of animals would only produce 
OPN in BM-derived cells such as monocytes/macrophages and, therefore, have no OPN 
in the ECM peripheral to the BM.  Conversely, the other set of animals would possess 
OPN in the ECM and tissue resident cells but have no OPN expression in BM-derived 
cells.  Then, it would be important to challenge these animals with hind limb ischemia or 
bone fracture and compare their responses relative to “control animals”, which in this 
case would be irradiated wild type mice receiving wild type BM and irradiated OPN-/- 
mice receiving OPN-/- bone marrow.  Using this experimental design, one could measure 
the relative importance of the contribution of OPN to ECM structure versus functionality 
of BM-derived monocyte / macrophage cells.  While this experimental design could 
potentially lend a great deal of insight into the mechanisms behind OPN functionality, it 
is not without significant assumptions.  For example, as mentioned in Chapter 2, EPCs 
are also believed to be derived from the bone marrow and to be important participants in 
neovascularization.  Therefore, the effects of BMT and the formation of the described 
chimeric mice on EPC activity could not be ignored.   
 Along those lines, it is also noteworthy to revisit two recent studies which have 
indicated that OPN plays a role in regulation of the hematopoietic stem cell (HSC) niche 
(171,172).  These investigators found aberrant localization and increased cycling of HSC 
in OPN-/- mice, and both studies, which were published within a few months of each 
other, independently concluded that OPN participates in HSC localization and as a 
negative regulator of HSC proliferation.  Functional effects of the role of OPN in 
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regulation of the HSC niche have yet to be determined.  As more completely discussed in 
Chapter 2, EPC mobilization and homing to sites of neovascularization are thought to be 
a vital part of the physiological response to pro-angiogenic cues.  These cells are believed 
to be derived from the HSC niche, and, therefore, their functionality could be affected by 
the absence of OPN.  Thus, one could hypothesize that EPC numbers, homing, or ability 
to incorporate into functional vasculature could be altered in the absence of OPN, and 
this could prove to be an important area for future studies.     
 Chapter 2 of this thesis summarized a number of in vitro cell signaling studies 
characterizing the multifaceted properties of OPN.  These previous studies have 
implicated OPN in cell survival, migration, and functionality of numerous cell types, and 
these effects are believed to be mediated through a wide variety of integrin and CD44 
receptors via intact OPN or cleavage fragments.  The importance of OPN in this sense 
has been well established.    However, the inherent complexity of this system has made it 
difficult to directly translate findings from studies in cells to a net effect in vivo.  The 
current thesis is comprised of many of the first studies that have carefully examined the 
overall importance of OPN on postnatal vascular growth and bone healing in living 
animals.  As summarized in Figure 6.5, these studies have allowed us to uncover 
significant, new findings and have allowed us to further speculate on what we believe to 
be the prominent mechanisms by which OPN exerts its effects.  However, as discussed in 
this chapter, much remains to be understood.  To this end, it is anticipated that the results 
of this work will spur further efforts that will lead to an even better understanding of both 
OPN functionality and the overall physiological control of postnatal vascular growth, 
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development and homeostasis of bone tissue mechanical integrity, and bone healing 

























Figure 6.5.  Flowchart displaying our hypothesized overall view on the effects of OPN 
deficiency in the animal models utilized in this dissertation.  It should be emphasized that 
reduced macrophage function is not thought to directly lead to reduced osteoclast 
function.  The right side of the flowchart is meant to infer that, since osteoclasts are 
derived from common haematopoietic progenitors and, therefore, closely related to 
macrophages, it is likely that OPN deficiency has parallel effects on the ability of these 
cells to carry out their specialized functions.  
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APPENDIX A 
MICRO-CT VASCULAR PREPARATION 
Reagents 
1. 0.9% normal saline 
2. Heparin 
3. Contrast agent 
4. 10% neutral buffered formalin 
Solutions 
1. 0.9% Normal saline (ie. 9 grams sodium chloride + 1000 ml deionized water) 
 
2. Heparinized Saline (100 units heparin/ml normal saline) 
 
3. *Note:  Nitric Oxide donors can be used to ensure vasodilation 
Materials 
1. Small surgical scissors, hemostat forceps, and small dissecting forceps 
 
2. 23 gauge butterfly needle  
 
3. IV drip bags with tubing or perfusion pump 
Procedure 
1. Make Heparinized Saline and prepare IV bags with saline/formalin 
2. Sacrifice animal by CO2 asphyxiation or over-anesthetization 
3. Prepare animal for perfusion 
a. Secure the animal on its back so that it is in a fully extended position. 
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b. Make a horizontal incision through the skin across the lower portion of the 
abdomen.  
c. Raise the skin with small forceps (to avoid cutting into organs) and make a 
superficial, vertical incision up to the sternum. 
d. Cut through the diaphragm to open the chest cavity, while avoiding cutting 
into the liver and lungs. 
e. Cut diagonally through the thoracic cage approximately halfway between 
the sternum and backbone in a “Y” pattern to make the heart accessible. 
f. Secure the lower part of the sternum with hemostat forceps and use the 
weight of the instrument to stabilize the ribcage in a cranial direction, 
exposing the heart. 
4. Perfuse heparinized saline at physiologic pressure (~100 mm Hg) through an IV 
drip bag or using a perfusion pump 
a. Gently hold the heart with forceps and insert a butterfly needle (attached 
to tubing) into the left ventricle. 
b. A small drop of superglue can be a useful means for stabilizing the 
interface between the needle and the heart.  
c. Cut the inferior vena cava (IVC) to create a vent to drain out re-circulating 
blood and perfusate. 
d. Start the flow of the saline. 
e. Perfuse approximately 10 minutes or until the internal organs become 
blanched in appearance.  The liver transitioning from a dark red to a light 
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grayish color is the best way to visually assess the completeness of the 
perfusion 
5. Pressure Fixation: 
a. Proceed with this step only after blood has been completely cleared with 
heparinized saline. 
b. Attach the reservoir containing 10% formalin to the butterfly needle, 
which should never be displaced from the left ventricle. 
c. Perfusion fix the animal with approximately 30- 50 mL 10% formalin. 
d. When fixation is complete, the animal should become very stiff and pale 
yellow in appearance. 
6. Briefly perfuse again with heparinized saline to clear the formalin from the 
vasculature 
7. Perfuse with the contrast agent of choice (ie. iodinated contrast solutions, 
polymerizing Microfil injection agents, or barium sulfate / gelatin suspensions): 
a. It may be easiest to inject the contrast agent using a 10 ml syringe that 
attaches to the butterfly needle.   
b. Perfuse approximately 10 ml or until you see contrast agent re-circulate 
from the IVC at the top of the liver. 
c. Internal organs including the liver, kidneys, etc. should turn the color of 
the injected contrast agent if applicable 
 
8. Dissect out the tissue of interest and immerse in 10% neutral buffered formalin 
until proceeding with micro-CT imaging.  For cases where the vasculature of 
interest is in close proximity to bone, soak the specimen in a formic acid or other 
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decalcification agent to reduce the attenuation of these hard tissues and facilitate 
global thresholding-based segmentation of the contrast filled vasculature from the 






HIND LIMB ISCHEMIA SURGERY 
Materials 
1. Small surgical scissors 
2. Hemostat forceps 
3. 2 small, curved dissecting forceps 
Procedure 
1. Sterilize instruments with glass bead sterilizer 
2. Anesthetize mouse 
3. Shave medial side of animals thigh from knee up 
4. Remove remainder of hair in this region with depilatory cream 
5. Cleanse skin with water to remove excess cream and hair and then clean skin with 
betadine 
6. Make a single longitudinal skin incision along the medial thigh that tracks the 
path of the femoral artery. 
7. Ligate the superficial femoral artery and vein proximal to the caudally branching 
deep femoral artery.  Be sure to separate the femoral nerve form the vessels at the 
ligation point and do not loop the sutures around the nerve.   
8. Perform the distal ligation just proximal to the branching of the tibial arteries.  
Again, do not ligate the nerve that is adjacent to the vessels being ligated. 
9. Dissect the length of the femoral artery/vein free from the musculature and free 
from the adjacent nerve between the two ligation points. 
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10. Cut any vessels that branch off of the artery/vein that have been dissected free 
tissue and excise the entire artery/vein located between the ligation points. 
11. Irrigate the surgical field and carefully close the skin incision using 5-0 silk 
sutures. 
12. Place Elizabethan collar on mouse to hinder the mouse from biting at 
wound/sutures. 
13. Allow the animal to awaken from anesthesia on a heating pad. 





FEMORAL FRACTURE SURGERY 
Materials 
1. Small surgical scissors 
2. Hemostat forceps 
3. Small dissecting forceps 
4. No. 15 scalpel 
Procedure 
1.  Sterilize instruments with glass bead sterilizer 
2. Anesthetize mouse 
3. Shave lateral side of animals thigh from knee up 
4. Remove remainder of hair in this region with depilatory cream 
5. Cleanse skin with water to remove excess cream and hair and then clean skin with 
betadine 
6. Make longitudinal skin incision along lateral side of leg from knee towards hip 
7. Using a No. 15 scalpel, make a longitudinal cut along the lateral condyle of the 
femur 
8. Tease apart the biceps femoris and vastus lateralis muscles to expose the lateral 
side of the femur 
9. Slide the patella to the medial side of the condyle 
10. Flex knee to expose the condyle and insert a 25-gauge needle retrograde into the 
intramedullary canal.  Note: I use the beveled needle to puncture the condyle and 
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then cut off the beveled “point” and then re-insert the needle to avoid puncturing 
the proximal end of the femur during insertion of the needle. 
11. Then, using the No. 15 scalpel, create a mid-diaphyseal transverse fracture 
12. Slide the needle slightly back out of the intramedullary canal of the femur and cut 
the needle to the appropriate length (so that the intramedullary support is flush 
with the surface of the condyle at the needle insertion point). 
13. Slide the patella back into its native position, covering the condyle. 
14. Using 5-0 silk sutures, place one suture to hold the biceps femoris and vastus 
lateralis muscles together. 
15. Place one suture connecting the patellar ligament to the adjacent musculature on 
the lateral side (to keep the patella from sliding back out of place). 
16. Close the skin incision using interrupted sutures and staples. 
17. Allow the animal to awaken from anesthesia on a heating pad. 
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